Cover Page
Cover Page - shares | 9 Months Ended | |
Sep. 30, 2021 | Oct. 29, 2021 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-36007 | |
Entity Registrant Name | PHYSICIANS REALTY TRUST | |
Entity Incorporation, State or Country Code | MD | |
Entity Tax Identification Number | 46-2519850 | |
Entity Address, Address Line One | 309 N. Water Street, Suite 500 | |
Entity Address, City or Town | Milwaukee, | |
Entity Address, State or Province | WI | |
Entity Address, Postal Zip Code | 53202 | |
City Area Code | 414 | |
Local Phone Number | 367-5600 | |
Title of 12(b) Security | Common stock, $0.01 par value per share | |
Trading Symbol | DOC | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Emerging Growth Company | false | |
Entity Small Business | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding (in shares) | 220,289,484 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q3 | |
Entity Central Index Key | 0001574540 | |
Current Fiscal Year End Date | --12-31 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Investment properties: | ||
Land and improvements | $ 231,162 | $ 231,621 |
Building and improvements | 3,879,810 | 3,824,796 |
Tenant improvements | 81,605 | 73,145 |
Acquired lease intangibles | 409,048 | 406,935 |
Gross real estate property | 4,601,625 | 4,536,497 |
Accumulated depreciation | (779,910) | (687,554) |
Net real estate property | 3,821,715 | 3,848,943 |
Real estate held for sale | 44,706 | 0 |
Right-of-use lease assets, net | 141,967 | 137,180 |
Real estate loans receivable, net | 181,125 | 198,800 |
Investments in unconsolidated entities | 78,562 | 77,755 |
Net real estate investments | 4,268,075 | 4,262,678 |
Cash and cash equivalents | 5,366 | 2,515 |
Tenant receivables, net | 5,545 | 4,757 |
Other assets | 130,489 | 144,000 |
Total assets | 4,409,475 | 4,413,950 |
Liabilities: | ||
Credit facility | 401,548 | 412,322 |
Notes payable | 969,313 | 968,653 |
Mortgage debt | 50,042 | 57,875 |
Accounts payable | 5,760 | 7,007 |
Dividends and distributions payable | 53,730 | 52,116 |
Accrued expenses and other liabilities | 79,621 | 91,929 |
Lease liabilities | 78,682 | 74,116 |
Acquired lease intangibles, net | 5,829 | 6,641 |
Total liabilities | 1,644,525 | 1,670,659 |
Redeemable noncontrolling interest - Series A Preferred Units and partially owned properties | 7,039 | 28,289 |
Equity: | ||
Common shares, $0.01 par value, 500,000,000 common shares authorized, 217,409,035 and 209,550,592 common shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively | 2,174 | 2,096 |
Additional paid-in capital | 3,443,748 | 3,303,231 |
Accumulated deficit | (751,150) | (658,171) |
Accumulated other comprehensive loss | (4,054) | (5,859) |
Total shareholders’ equity | 2,690,718 | 2,641,297 |
Noncontrolling interests: | ||
Operating Partnership | 66,736 | 73,302 |
Partially owned properties | 457 | 403 |
Total noncontrolling interests | 67,193 | 73,705 |
Total equity | 2,757,911 | 2,715,002 |
Total liabilities and equity | $ 4,409,475 | $ 4,413,950 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Sep. 30, 2021 | Dec. 31, 2020 |
Equity: | ||
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 500,000,000 | 500,000,000 |
Common stock, shares outstanding (in shares) | 217,409,035 | 209,550,592 |
Common stock, shares issued (in shares) | 217,409,035 | 209,550,592 |
Consolidated Statements of Inco
Consolidated Statements of Income - USD ($) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | ||
Revenues: | |||||
Rental and related revenues | $ 110,314,000 | $ 104,362,000 | $ 326,017,000 | $ 311,861,000 | |
Interest income on real estate loans and other | 4,997,000 | 5,204,000 | 15,558,000 | 14,199,000 | |
Total revenues | 115,311,000 | 109,566,000 | 341,575,000 | 326,060,000 | |
Expenses: | |||||
Interest expense | 13,498,000 | 13,698,000 | 40,754,000 | 43,521,000 | |
General and administrative | 9,534,000 | 8,346,000 | 28,116,000 | 25,565,000 | |
Operating expenses | 35,679,000 | 32,503,000 | 103,069,000 | 94,495,000 | |
Depreciation and amortization | 38,582,000 | 37,952,000 | 114,663,000 | 111,744,000 | |
Impairment loss | 340,000 | 0 | 340,000 | 0 | |
Total expenses | 97,633,000 | 92,499,000 | 286,942,000 | 275,325,000 | |
Income before equity in loss of unconsolidated entities and gain on sale of investment properties, net: | 17,678,000 | 17,067,000 | 54,633,000 | 50,735,000 | |
Equity in loss of unconsolidated entities | (390,000) | (592,000) | (1,213,000) | (856,000) | |
Gain on sale of investment properties, net | 4,757,000 | 0 | 5,111,000 | 0 | |
Net income | 22,045,000 | 16,475,000 | 58,531,000 | 49,879,000 | |
Net income attributable to noncontrolling interests: | |||||
Operating Partnership | (529,000) | (425,000) | (1,405,000) | (1,305,000) | |
Partially owned properties | [1] | (152,000) | (151,000) | (455,000) | (441,000) |
Net income attributable to controlling interest | 21,364,000 | 15,899,000 | 56,671,000 | 48,133,000 | |
Preferred distributions | 0 | (317,000) | (13,000) | (951,000) | |
Net income attributable to common shareholders | $ 21,364,000 | $ 15,582,000 | $ 56,658,000 | $ 47,182,000 | |
Net income per share: | |||||
Basic (in dollars per share) | $ 0.10 | $ 0.07 | $ 0.26 | $ 0.23 | |
Diluted (in dollars per share) | $ 0.10 | $ 0.07 | $ 0.26 | $ 0.23 | |
Weighted average common shares: | |||||
Weighted average common shares - basic (in shares) | 217,406,657 | 208,187,129 | 214,616,482 | 202,717,190 | |
Weighted average common shares - diluted (in shares) | 223,992,049 | 215,129,968 | 221,399,649 | 209,555,060 | |
Dividends and distributions declared per common share (in usd per share) | $ 0.23 | $ 0.23 | $ 0.69 | $ 0.69 | |
[1] | Includes amounts attributable to redeemable noncontrolling interests. |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 22,045 | $ 16,475 | $ 58,531 | $ 49,879 |
Other comprehensive income (loss): | ||||
Change in fair value of interest rate swap agreements, net | 465 | 599 | 1,805 | (10,630) |
Total other comprehensive income (loss) | 465 | 599 | 1,805 | (10,630) |
Comprehensive income | 22,510 | 17,074 | 60,336 | 39,249 |
Comprehensive income attributable to noncontrolling interests - Operating Partnership | (541) | (442) | (1,449) | (1,024) |
Comprehensive income attributable to noncontrolling interests - partially owned properties | (152) | (151) | (455) | (441) |
Comprehensive income attributable to common shareholders | $ 21,817 | $ 16,481 | $ 58,432 | $ 37,784 |
Consolidated Statement of Equit
Consolidated Statement of Equity - USD ($) $ in Thousands | Total | Cumulative effect of changes in accounting standard | Total Shareholders’ Equity | Total Shareholders’ EquityCumulative effect of changes in accounting standard | Par Value | Additional Paid in Capital | Additional Paid in CapitalCumulative effect of changes in accounting standard | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) | Total Noncontrolling Interests | Operating Partnership Noncontrolling Interest | Partially Owned Properties Noncontrolling Interest |
Balance at Dec. 31, 2019 | $ 2,480,984 | $ (147) | $ 2,408,948 | $ (147) | $ 1,900 | $ 2,931,921 | $ (147) | $ (529,194) | $ 4,321 | $ 72,036 | $ 71,697 | $ 339 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
Net proceeds from sale of common shares | 239,232 | 239,232 | 124 | 239,108 | ||||||||
Restricted share award grants, net | (201) | (201) | 2 | 245 | (448) | |||||||
Purchase of OP Units | (93) | (93) | (93) | |||||||||
Dividends/distributions declared | (47,911) | (46,636) | (46,636) | (1,275) | (1,275) | |||||||
Preferred distributions | (317) | (317) | (317) | |||||||||
Distributions | (41) | (41) | (41) | |||||||||
Change in market value of Redeemable Noncontrolling Interest in Operating Partnership | (980) | (980) | 581 | (1,561) | ||||||||
Change in fair value of interest rate swap agreements | (9,986) | (9,986) | (9,986) | |||||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | 0 | (2,038) | (2,038) | 2,038 | 2,038 | |||||||
Net income | 14,885 | 14,414 | 14,414 | 471 | 404 | 67 | ||||||
Balance at Mar. 31, 2020 | 2,675,425 | 2,602,289 | 2,026 | 3,169,670 | (563,742) | (5,665) | 73,136 | 72,771 | 365 | |||
Balance at Dec. 31, 2019 | 2,480,984 | $ (147) | 2,408,948 | $ (147) | 1,900 | 2,931,921 | $ (147) | (529,194) | 4,321 | 72,036 | 71,697 | 339 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
Change in fair value of interest rate swap agreements | (10,630) | |||||||||||
Balance at Sep. 30, 2020 | 2,715,183 | 2,643,076 | 2,082 | 3,275,187 | (627,884) | (6,309) | 72,107 | 71,676 | 431 | |||
Balance at Mar. 31, 2020 | 2,675,425 | 2,602,289 | 2,026 | 3,169,670 | (563,742) | (5,665) | 73,136 | 72,771 | 365 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
Net proceeds from sale of common shares | 99,505 | 99,505 | 55 | 99,450 | ||||||||
Restricted share award grants, net | 2,226 | 2,226 | 3,017 | (791) | ||||||||
Purchase of OP Units | (67) | (67) | (67) | |||||||||
Dividends/distributions declared | (49,195) | (47,924) | (47,924) | (1,271) | (1,271) | |||||||
Preferred distributions | (317) | (317) | (317) | |||||||||
Distributions | (42) | (42) | (42) | |||||||||
Change in market value of Redeemable Noncontrolling Interest in Operating Partnership | (579) | (579) | (416) | (163) | ||||||||
Change in fair value of interest rate swap agreements | (1,243) | (1,243) | (1,243) | |||||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | 0 | (806) | (806) | 806 | 806 | |||||||
Net income | 18,369 | 17,820 | 17,820 | 549 | 476 | 73 | ||||||
Balance at Jun. 30, 2020 | 2,744,082 | 2,670,971 | 2,081 | 3,270,915 | (595,117) | (6,908) | 73,111 | 72,715 | 396 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
Net proceeds from sale of common shares | 1,529 | 1,529 | 1 | 1,528 | ||||||||
Restricted share award grants, net | 2,458 | 2,458 | 2,951 | (493) | ||||||||
Purchase of OP Units | (355) | (355) | (355) | |||||||||
Dividends/distributions declared | (49,214) | (47,943) | (47,943) | (1,271) | (1,271) | |||||||
Preferred distributions | (317) | (317) | (317) | |||||||||
Distributions | (41) | (41) | (41) | |||||||||
Change in market value of Redeemable Noncontrolling Interest in Operating Partnership | 42 | 42 | (45) | 87 | ||||||||
Change in fair value of interest rate swap agreements | 599 | 599 | 599 | |||||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | 0 | (162) | (162) | 162 | 162 | |||||||
Net income | 16,400 | 15,899 | 15,899 | 501 | 425 | 76 | ||||||
Balance at Sep. 30, 2020 | 2,715,183 | 2,643,076 | 2,082 | 3,275,187 | (627,884) | (6,309) | 72,107 | 71,676 | 431 | |||
Balance at Dec. 31, 2020 | 2,715,002 | 2,641,297 | 2,096 | 3,303,231 | (658,171) | (5,859) | 73,705 | 73,302 | 403 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
Net proceeds from sale of common shares | 52,432 | 52,432 | 28 | 52,404 | ||||||||
Restricted share award grants, net | (993) | (993) | 4 | (333) | (664) | |||||||
Purchase of OP Units | (269) | (269) | (269) | |||||||||
Dividends/distributions declared | (50,254) | (49,011) | (49,011) | (1,243) | (1,243) | |||||||
Preferred distributions | (13) | (13) | (13) | |||||||||
Distributions | (73) | (73) | (73) | |||||||||
Change in market value of Redeemable Noncontrolling Interest in Operating Partnership | 873 | 873 | (23) | 896 | ||||||||
Change in fair value of interest rate swap agreements | 797 | 797 | 797 | |||||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | 0 | 1,136 | 1,136 | (1,136) | (1,136) | |||||||
Net income | 17,729 | 17,194 | 17,194 | 535 | 459 | 76 | ||||||
Balance at Mar. 31, 2021 | 2,735,231 | 2,663,712 | 2,128 | 3,356,415 | (689,769) | (5,062) | 71,519 | 71,113 | 406 | |||
Balance at Dec. 31, 2020 | 2,715,002 | 2,641,297 | 2,096 | 3,303,231 | (658,171) | (5,859) | 73,705 | 73,302 | 403 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
Change in fair value of interest rate swap agreements | 1,805 | |||||||||||
Balance at Sep. 30, 2021 | 2,757,911 | 2,690,718 | 2,174 | 3,443,748 | (751,150) | (4,054) | 67,193 | 66,736 | 457 | |||
Balance at Mar. 31, 2021 | 2,735,231 | 2,663,712 | 2,128 | 3,356,415 | (689,769) | (5,062) | 71,519 | 71,113 | 406 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
Net proceeds from sale of common shares | 82,827 | 82,827 | 46 | 82,781 | ||||||||
Restricted share award grants, net | 2,760 | 2,760 | 3,242 | (482) | ||||||||
Purchase of OP Units | (5,063) | (5,063) | (5,063) | |||||||||
Dividends/distributions declared | (51,303) | (50,061) | (50,061) | (1,242) | (1,242) | |||||||
Distributions | (50) | (50) | (50) | |||||||||
Change in market value of Redeemable Noncontrolling Interest in Operating Partnership | (388) | (388) | (388) | |||||||||
Change in fair value of interest rate swap agreements | 543 | 543 | 543 | |||||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | 0 | (2,124) | (2,124) | 2,124 | 2,124 | |||||||
Net income | 18,606 | 18,113 | 18,113 | 493 | 417 | 76 | ||||||
Balance at Jun. 30, 2021 | 2,783,163 | 2,715,382 | 2,174 | 3,440,314 | (722,587) | (4,519) | 67,781 | 67,349 | 432 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||||
Net proceeds from sale of common shares | (117) | (117) | (117) | |||||||||
Restricted share award grants, net | 3,755 | 3,755 | 3,642 | 113 | ||||||||
Dividends/distributions declared | (51,295) | (50,062) | (50,062) | (1,233) | (1,233) | |||||||
Distributions | (51) | (51) | (51) | |||||||||
Change in market value of Redeemable Noncontrolling Interest in Operating Partnership | 22 | 22 | 22 | |||||||||
Change in fair value of interest rate swap agreements | 465 | 465 | 465 | |||||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | 0 | (91) | (91) | 91 | 91 | |||||||
Net income | 21,969 | 21,364 | 21,364 | 605 | 529 | 76 | ||||||
Balance at Sep. 30, 2021 | $ 2,757,911 | $ 2,690,718 | $ 2,174 | $ 3,443,748 | $ (751,150) | $ (4,054) | $ 67,193 | $ 66,736 | $ 457 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Cash Flows from Operating Activities: | ||
Net income | $ 58,531,000 | $ 49,879,000 |
Adjustments to reconcile net income to net cash provided by operating activities | ||
Depreciation and amortization | 114,663,000 | 111,744,000 |
Amortization of deferred financing costs | 1,744,000 | 1,789,000 |
Amortization of lease inducements and above/below-market lease intangibles | 3,526,000 | 3,504,000 |
Straight-line rental revenue/expense | (7,276,000) | (9,624,000) |
Amortization of discount on unsecured senior notes | 489,000 | 469,000 |
Amortization of above market assumed debt | (47,000) | (47,000) |
Gain on sale of investment properties, net | (5,111,000) | 0 |
Equity in loss of unconsolidated entities | 1,213,000 | 856,000 |
Distributions from unconsolidated entities | 5,261,000 | 4,305,000 |
Change in fair value of derivative | 0 | 15,000 |
Provision for bad debts | (139,000) | 512,000 |
Non-cash share compensation | 10,840,000 | 9,161,000 |
Net change in fair value of contingent consideration | 0 | (715,000) |
Impairment loss | 340,000 | 0 |
Change in operating assets and liabilities: | ||
Tenant receivables | (2,913,000) | 626,000 |
Other assets | 3,300,000 | (6,777,000) |
Accounts payable | (1,247,000) | 1,774,000 |
Accrued expenses and other liabilities | (7,427,000) | (1,111,000) |
Net cash provided by operating activities | 175,747,000 | 166,360,000 |
Cash Flows from Investing Activities: | ||
Proceeds from sale of investment properties | 31,093,000 | 0 |
Acquisition of investment properties, net | (120,617,000) | (34,529,000) |
Investment in unconsolidated entities | (7,281,000) | 0 |
Escrowed cash - acquisition deposits/earnest deposits | (1,154,000) | (150,000) |
Capital expenditures on investment properties | (22,159,000) | (20,673,000) |
Investment in real estate loans receivable | (14,406,000) | (32,630,000) |
Repayment of real estate loans receivable | 18,902,000 | 944,000 |
Leasing commissions | (3,343,000) | (1,887,000) |
Net cash used in investing activities | (118,965,000) | (88,925,000) |
Cash Flows from Financing Activities: | ||
Net proceeds from sale of common shares | 135,142,000 | 340,266,000 |
Proceeds from credit facility borrowings | 304,000,000 | 235,000,000 |
Repayment of credit facility borrowings | (311,000,000) | (479,000,000) |
Principal payments on mortgage debt | (7,833,000) | (24,974,000) |
Debt issuance costs | (5,300,000) | (63,000) |
Payments made on financing lease | (1,700,000) | 0 |
Dividends paid - shareholders | (148,478,000) | (138,778,000) |
Distributions to noncontrolling interests - Operating Partnership | (3,792,000) | (3,821,000) |
Preferred distributions paid - OP Unit holder | (303,000) | (951,000) |
Distributions to noncontrolling interests - partially owned properties | (491,000) | (437,000) |
Payments of employee taxes for withheld stock-based compensation shares | (4,183,000) | (2,848,000) |
Purchase of Series A Preferred Units | (4,661,000) | 0 |
Purchase of OP Units | (5,332,000) | (515,000) |
Net cash used in financing activities | (53,931,000) | (76,121,000) |
Net increase in cash and cash equivalents | 2,851,000 | 1,314,000 |
Cash and cash equivalents, beginning of period | 2,515,000 | 2,355,000 |
Cash and cash equivalents, end of period | 5,366,000 | 3,669,000 |
Supplemental Cash Flow Information [Abstract] | ||
Supplemental disclosure of cash flow information - interest paid during the period | 49,160,000 | 52,000,000 |
Supplemental disclosure of noncash activity—settlement of note receivable in exchange for Series A Preferred Units | 20,646,000 | 0 |
Supplemental disclosure of noncash activity—change in fair value of interest rate swap agreements | 1,805,000 | (10,630,000) |
Supplemental disclosure of noncash activity—Conversion of loan receivable in connection to the acquisition of investment property | $ 15,500,000 | $ 0 |
Organization and Business
Organization and Business | 9 Months Ended |
Sep. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Business | Organization and Business Physicians Realty Trust (the “Trust” or the “Company”) was organized in the state of Maryland on April 9, 2013. As of September 30, 2021, the Trust was authorized to issue up to 500,000,000 common shares of beneficial interest, par value $0.01 per share. The Trust filed a Registration Statement on Form S-11 with the Commission with respect to a proposed underwritten initial public offering (the “IPO”) and completed the IPO of its common shares and commenced operations on July 24, 2013. The Trust contributed the net proceeds from the IPO to Physicians Realty L.P, a Delaware limited partnership (the “Operating Partnership”), and is the sole general partner of the Operating Partnership. The Trust’s operations are conducted through the Operating Partnership and wholly-owned and majority-owned subsidiaries of the Operating Partnership. The Trust, as the general partner of the Operating Partnership, controls the Operating Partnership and consolidates the assets, liabilities, and results of operations of the Operating Partnership. The Trust is a self-managed REIT formed primarily to acquire, selectively develop, own, and manage health care properties that are leased to physicians, hospitals, and health care delivery systems. ATM Program In November 2019, the Trust and the Operating Partnership entered into separate At Market Issuance Sales Agreements (the “2019 Sales Agreements”) with each of KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., BMO Capital Markets Corp., Raymond James & Associates, Inc., and Stifel, Nicolaus & Company, Incorporated, in their capacity as agents and as forward sellers (the “2019 Agents”), pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $500 million, through the 2019 Agents (the “2019 ATM Program”). The 2019 Sales Agreements contemplate that, in addition to the issuance and sale of the Trust’s common shares through the 2019 Agents, the Trust may also enter into one or more forward sales agreements from time to time in the future with each of KeyBanc Capital Markets, Inc., Credit Agricole Securities (USA) Inc., BMO Capital Markets Corp., Raymond James & Associates, Inc., and Stifel, Nicolaus & Company, Incorporated, or one of their respective affiliates. In May 2021, the Trust and the Operating Partnership entered into an At Market Issuance Sales Agreement (the “2021 Sales Agreement”) with KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., BMO Capital Markets Corp., and Raymond James & Associates, Inc. in their capacity as agents for the Company and/or forward sellers and Stifel, Nicolaus & Company, Incorporated in its capacity as sales agent for the Company (collectively, the “2021 Agents”) and Bank of Montreal, Credit Agricole Corporate and Investments Bank, KeyBanc Capital Markets Inc., and Raymond James & Associates, Inc. as forward purchasers for the Company (the “Forward Purchasers”), pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $500 million through the 2021 Agents (the “2021 ATM Program”). The 2021 Sales Agreement contemplates that, in addition to the issuance and sale of the Trust’s common shares through the 2021 Agents, the Trust may also enter into one or more forward sales agreements from time to time in the future with each of the Forward Purchasers. Upon entry into the 2021 Sales Agreement, we terminated the 2019 ATM Program. During the quarterly periods ended March 31, 2021, June 30, 2021, and September 30, 2021, the Trust’s issuance and sale of common shares pursuant to the ATM Programs is as follows (in thousands, except common shares and price): Common Weighted average price Net Quarterly period ended March 31, 2021 2,887,296 $ 18.32 $ 52,358 Quarterly period ended June 30, 2021 4,532,343 18.39 82,519 Quarterly period ended September 30, 2021 — — — Year to date 7,419,639 $ 18.36 $ 134,877 As of September 30, 2021, the Trust has $465.3 million remaining available under the 2021 ATM Program. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies The accompanying unaudited consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the periods ended September 30, 2021 and 2020 pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited financial statements included in the Trust’s 2020 Annual Report. The Company has consistently applied its accounting policies to all periods presented in these consolidated financial statements. Noncontrolling Interests As of September 30, 2021, the Trust held a 97.6% interest in the Operating Partnership. As the sole general partner and the majority interest holder, the Trust consolidates the financial position and results of operations of the Operating Partnership. Redeemable Noncontrolling Interests - Series A Preferred Units and Partially Owned Properties In connection with the acquisition of the HealthEast Clinic & Specialty Center (“Hazelwood Medical Commons Transaction”) that occurred on January 9, 2018, the Company issued 116,110 Series A Participating Redeemable Preferred Units of the Operating Partnership (“Series A Preferred Units”). On January 4, 2021, these Series A Preferred Units were redeemed for a total value of $25.3 million and as a result of this redemption, there are no Series A Preferred Units outstanding as of September 30, 2021. In connection with the Company’s acquisitions of the medical office building, ambulatory surgery center, and hospital located on the Great Falls Hospital campus in Great Falls, Montana, physicians affiliated with the sellers retained non-controlling interests which may, at the holders’ option, be redeemed at any time after May 1, 2023. Due to the redemption provision, which is outside of the control of the Trust, the Trust classifies the investment in the mezzanine section of its consolidated balance sheets. The Trust records the carrying amount of the redeemable noncontrolling interests at the greater of the carrying value or redemption value. Dividends and Distributions On September 22, 2021, the Trust announced that its Board of Trustees authorized and the Trust declared a cash dividend of $0.23 per common share for the quarterly period ended September 30, 2021. The dividend was paid on October 15, 2021 to common shareholders and holders of record of partnership interests of the Operating Partnership (“OP Units”) as of the close of business on October 4, 2021. Tax Status of Dividends and Distributions The Company’s distributions of current and accumulated earnings and profits for U.S. federal income tax purposes generally are taxable to shareholders as ordinary income. Distributions in excess of these earnings and profits generally are treated as a non-taxable reduction of the shareholders’ basis in the shares to the extent thereof (non-dividend distributions) and thereafter as taxable gain. Any cash distributions received by an OP Unit holder in respect of its OP Units generally will not be taxable to such OP Unit holder for U.S. federal income tax purposes, to the extent that such distribution does not exceed the OP Unit holder’s basis in its OP Units. Any such distribution will instead reduce the OP Unit holder’s basis in its OP Units (and OP Unit holders will be subject to tax on the taxable income allocated to them by the Operating Partnership in respect of their OP Units when such income is earned by the Operating Partnership, with such income allocation increasing the OP Unit holders’ basis in their OP Units). Impairment of Intangible and Long-Lived Assets The Company periodically evaluates its long-lived assets, primarily consisting of investments in real estate, for impairment indicators or whenever events or changes in circumstances indicate that the recorded amount of an asset may not be fully recoverable. The Company recorded a $0.3 million impairment charge for the three and nine months ended September 30, 2021, and did not record an impairment charge for the three and nine months ended September 30, 2020. Assets Held for Sale The Company may sell properties from time to time for various reasons, including favorable market conditions. The Company classifies certain long-lived assets as held for sale once the criteria, as defined by GAAP, have been met. The Company classifies a real estate property as held for sale when: (i) management has approved the disposition of the property, (ii) the property is available for sale in its present condition, (iii) an active program to locate a buyer has been initiated, (iv) it is probable that the property will be disposed of within one year, (v) the property is being marketed at a reasonable price relative to its fair value, and (vi) it is unlikely that the disposition plan will significantly change or be withdrawn. Following the classification of a property as “held for sale,” no further depreciation or amortization is recorded for the asset and the book value of the asset is written down to the lower of carrying value or fair market value, less cost to sell . As of September 30, 2021, the Company classified four properties as held for sale. Real Estate Loans Receivable, Net Real estate loans receivable consists of 22 mezzanine loans, three term loans, and one construction loan as of September 30, 2021. Generally, each mezzanine loan is collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner, each term loan is secured by a mortgage of a related medical office building, and construction loans are secured by mortgages on the land and the improvements as constructed. In accordance with the adoption of ASU 2016-13, Financial Instruments - Credit Losses (“ASU 2016-13”) on January 1, 2020, the Company adjusted the opening balance of retained earnings by $0.1 million. The reserve for loan losses was $0.1 million as of September 30, 2021. Rental and Related Revenues Rental revenue is recognized on a straight-line basis over the terms of the related leases when collectability is probable. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue for amounts more or less than amounts currently due from tenants. Amounts recognized in excess of amounts currently due from tenants, excluding assets classified as held for sale, are included in other assets and were approximately $93.7 million and $86.6 million as of September 30, 2021 and December 31, 2020, respectively. If the Company determines that collectability of straight-line rents is not probable, income recognition is limited to the lesser of cash collected, or lease income reflected on a straight-line basis, plus variable rent when it becomes accruable. In accordance with ASC 842, Leases , if the collectability of a lease changes after the commencement date, any difference between lease income that would have been recognized and the lease payments shall be recognized as an adjustment to lease income. Bad debt recognized as an adjustment to rental and related revenues was insignificant for the three and nine months ended September 30, 2021. Bad debt recognized as an adjustment to rental and related revenues was $0.4 million and $0.5 million for the three and nine months ended September 30, 2020, respectively. Rental revenue is adjusted by the amortization of lease inducements and above-market or below-market rents on certain leases. Lease inducements and above-market or below-market rents are amortized on a straight-line basis over the remaining lease term. Rental and related revenues also include expense recoveries, which relate to tenant reimbursement of real estate taxes, insurance, and other operating expenses that are recognized in the period the applicable expenses are incurred. The reimbursements are recorded gross, as the Company is generally the primary obligor with respect to real estate taxes and purchasing goods and services from third-party suppliers, has discretion in selecting the supplier, and bears the credit risk of tenant reimbursement. New Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which changes the impairment model for most financial instruments by requiring companies to recognize an allowance for expected losses, rather than incur losses as required previously by the other-than-temporary impairment model. ASU 2016-13 applies to most financial assets measured at amortized cost and certain other instruments, including certain receivables, loans, held-to-maturity debt securities, net investments in leases, and off-balance-sheet credit exposures (e.g., loan commitments). ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19 also clarifies that receivables arising from operating leases are not within the scope of Subtopic 326-20. Instead, impairment of these receivables should be accounted for in accordance with ASC 842. The Company has adopted ASU 2016-13 as of the effective date, January 1, 2020, with a cumulative effect adjustment to the opening balance of retained earnings of $0.1 million. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting , that provides optional relief to applying reference rate reform to changing reference rates, contracts, hedging relationships, and other transactions that reference LIBOR, which will be discontinued by the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. The Company is evaluating how the transition away from LIBOR will impact the Company, and if the optional relief in this standard will be adopted. The Company does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements if adopted. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) , which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, with early adoption permitted. The Company is currently evaluating the impact ASU 2020-06 will have on its consolidated financial statements. |
Investment and Disposition Acti
Investment and Disposition Activity | 9 Months Ended |
Sep. 30, 2021 | |
Business Combination and Asset Acquisition [Abstract] | |
Investment and Disposition Activity | Investment and Disposition Activity During the nine months ended September 30, 2021, the Company completed the acquisition of eight medical office facilities and three medical condominium units for an aggregate investment of approximately $122.7 million, excluding the conversion of a previously outstanding construction loan of $15.5 million. The Company also funded three mezzanine loans for $8.9 million and closed on a $10.5 million construction loan, funding $5.5 million as of September 30, 2021. Additionally, the Company acquired a membership interest in one joint venture for $7.3 million and paid $0.3 million of additional purchase consideration under an earn-out agreement, resulting in total investment activity of approximately $144.7 million. As part of these investments, the Company incurred approximately $1.6 million of capitalized costs. Investment activity for the three months ended September 30, 2021 is summarized below: Investment (1) Location Acquisition Investment Amount InterMed MOB - Davis Joint Venture (2) Portland, ME August 18, 2021 $ 7,291 Atkins Portfolio (5 MOBs) Various August 30, 2021 54,090 HonorHealth - Sonoran MOB Phoenix, AZ September 23, 2021 31,750 Loan Investments Various Various 3,734 $ 96,865 (1) “MOB” means medical office building (2) The Company purchased a 49% membership interest in this property through the Davis Joint Venture. The following table summarizes the acquisition date fair values of the assets acquired and the liabilities assumed during the nine months ended September 30, 2021, which the Company determined using Level 2 and Level 3 inputs (in thousands): 1st Quarter 2nd Quarter 3rd Quarter Total Land $ 189 $ 2,655 $ 8,054 $ 10,898 Building and improvements 917 44,743 66,652 112,312 In-place lease intangibles 29 4,442 8,216 12,687 Above market in-place lease intangibles — — 241 241 Below market in-place lease intangibles — — (151) (151) Right-of-use asset — — 1,700 1,700 Prepaid expenses — 129 — 129 Net assets acquired $ 1,135 $ 51,969 $ 84,712 $ 137,816 Assets Held for Sale As of September 30, 2021, the Company classified four assets as held for sale. In accordance with this classification, the following assets are classified as held for sale in the accompanying consolidated balance sheets at September 30, 2021 (in thousands). Land and improvements $ 7,660 Building and improvements 49,930 Tenant improvements 455 Acquired lease intangibles 3,141 Real estate held for sale before accumulated depreciation 61,186 Accumulated depreciation (16,480) Real estate held for sale $ 44,706 |
Intangibles
Intangibles | 9 Months Ended |
Sep. 30, 2021 | |
Finite-Lived Intangible Assets, Net [Abstract] | |
Intangibles | Intangibles The following is a summary of the carrying amount of intangible assets and liabilities, excluding assets classified as held for sale if applicable, as of September 30, 2021 and December 31, 2020 (in thousands): September 30, 2021 December 31, 2020 Cost Accumulated Net Cost Accumulated Net Assets In-place leases $ 364,750 $ (193,231) $ 171,519 $ 362,837 $ (173,862) $ 188,975 Above-market leases $ 43,586 $ (23,373) $ 20,213 $ 43,386 $ (20,670) $ 22,716 Leasehold interest $ 712 $ (406) $ 306 $ 712 $ (361) $ 351 Liabilities Below-market leases $ 15,980 $ (10,151) $ 5,829 $ 15,882 $ (9,241) $ 6,641 The following is a summary of acquired lease intangible amortization for the three and nine month periods ended September 30, 2021 and 2020 (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Amortization expense related to in-place leases $ 8,103 $ 9,088 $ 24,590 $ 26,190 Decrease in rental income related to above-market leases 897 954 2,744 2,918 Decrease in rental income related to leasehold interest 15 15 45 45 Increase in rental income related to below-market leases 324 397 963 1,102 Future aggregate net amortization of acquired lease intangibles, excluding four assets classified as held for sale, as of September 30, 2021, is as follows (in thousands): Net Decrease in Net Increase in 2021 $ 547 $ 7,954 2022 1,963 29,276 2023 1,656 26,546 2024 1,589 23,350 2025 1,590 19,817 Thereafter 7,345 64,576 Total $ 14,690 $ 171,519 |
Other Assets
Other Assets | 9 Months Ended |
Sep. 30, 2021 | |
Other Assets, Unclassified [Abstract] | |
Other Assets | Other Assets Other assets consisted of the following, excluding assets classified as held for sale if applicable, as of September 30, 2021 and December 31, 2020 (in thousands): September 30, December 31, Straight line rent receivable, net $ 93,747 $ 86,551 Leasing commissions, net 11,441 9,282 Prepaid expenses 8,943 9,401 Lease inducements, net 8,518 9,396 Escrows 1,546 1,507 Notes receivable, net 1,045 23,760 Other 5,249 4,103 Total $ 130,489 $ 144,000 |
Debt
Debt | 9 Months Ended |
Sep. 30, 2021 | |
Debt Disclosure [Abstract] | |
Debt | Debt The following is a summary of debt as of September 30, 2021 and December 31, 2020 (in thousands): September 30, December 31, Fixed interest mortgage notes (1) $ 44,420 $ 51,896 Variable interest mortgage note (2) 5,748 6,105 Total mortgage debt 50,168 58,001 Unsecured revolving credit facility bearing variable interest (3) 159,000 166,000 $400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027 400,000 400,000 $350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028 350,000 350,000 $250 million unsecured term borrowing bearing fixed interest of 2.07%, due June 2023 (4) 250,000 250,000 $150 million senior unsecured notes bearing fixed interest of 4.03% to 4.74%, due January 2023 to 2031 150,000 150,000 $75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027 75,000 75,000 Total principal 1,434,168 1,449,001 Unamortized deferred financing costs (8,925) (5,369) Unamortized discounts (4,366) (4,855) Unamortized fair value adjustments 26 73 Total debt $ 1,420,903 $ 1,438,850 (1) As of September 30, 2021, fixed interest mortgage notes bear interest from 4.63% to 5.50%, due in 2022 and 2024, with a weighted average interest rate of 4.79%. As of December 31, 2020, fixed interest mortgage notes bear interest from 4.63% to 5.50%, due in 2021, 2022, and 2024, with a weighted average interest rate of 4.78%. The notes are collateralized by three properties with a net book value of $97.0 million as of September 30, 2021 and four properties with a net book value of $110.3 million as of December 31, 2020. (2) Variable interest mortgage note bears variable interest of LIBOR plus 2.75%, for an interest rate of 2.83% and 2.90% as of September 30, 2021 and December 31, 2020, respectively. The note is due in 2028 and is collateralized by one property with a net book value of $8.1 million as of September 30, 2021 and $8.3 million as of December 31, 2020. (3) As of September 30, 2021, the amount of commitments under the revolving credit facility was $1.0 billion bearing variable interest of LIBOR plus 0.85%, due September 2025. As of December 31, 2020, the amount of commitments under the revolving credit facility was $850.0 million bearing variable interest of LIBOR plus 0.90%, due September 2022. (4) The Operating Partnership’s borrowings under the term loan feature of the Credit Agreement bears interest at a rate which is determined by the Trust’s credit rating, currently equal to LIBOR + 1.00%. The Operating Partnership has entered into a pay-fixed receive-variable interest rate swap, fixing the LIBOR component of this rate at 1.07%. On September 24, 2021, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a Third Amended and Restated Credit Agreement (the “Credit Agreement”) which extended the maturity date of the revolving credit facility under the Credit Agreement to September 24, 2025 and reduced the interest rate margin applicable to borrowings. The Credit Agreement includes an unsecured revolving credit facility of $1.0 billion and contains a term loan feature of $250.0 million, bringing total borrowing capacity to $1.3 billion. The Credit Agreement also includes a swingline loan commitment for up to 10% of the maximum principal amount and provides an accordion feature allowing the Operating Partnership to increase borrowing capacity by up to an additional $500.0 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of $1.75 billion. The revolving credit facility under the Credit Agreement also includes two, six-month extension options. Borrowings under the Credit Agreement bear interest on the outstanding principal amount at an adjusted LIBOR rate, which is based on the Trust’s investment grade rating under the Credit Agreement. As of September 30, 2021, the Trust had investment grade ratings of BBB from S&P, Baa2 from Moody’s, and BBB from Fitch. As such, borrowings under the revolving credit facility of the Credit Agreement accrue interest on the outstanding principal at a rate of LIBOR + 0.85%. The Credit Agreement includes a facility fee equal to 0.20% per annum, which is also determined by the Trust’s investment grade rating. On July 7, 2016, the Operating Partnership borrowed $250.0 million under the 7-year term loan feature of the Credit Agreement. Pursuant to the Credit Agreement, borrowings under the term loan feature of the Credit Agreement bear interest on the outstanding principal amount at a rate which is determined by the Trust’s credit rating, currently equal to LIBOR + 1.00%. The Operating Partnership simultaneously entered into a pay-fixed receive-variable rate swap for the full borrowing amount, fixing the LIBOR component of the borrowing rate to 1.07%, for a current all-in fixed rate of 2.07%. Both the borrowing and pay-fixed receive-variable swap have a maturity date of June 10, 2023. Base Rate Loans, Adjusted LIBOR Rate Loans, and Letters of Credit (each, as defined in the Credit Agreement) will be subject to interest rates, based upon the Trust’s investment grade rating as follows: Credit Rating Applicable Margin for Revolving Loans: LIBOR Rate Loans Applicable Margin for Revolving Loans: Base Rate Loans Applicable Margin for Term Loans: LIBOR Rate Loans Applicable Margin for Term Loans: Base Rate Loans At Least A- or A3 LIBOR + 0.725% — % LIBOR + 0.85% — % At Least BBB+ or Baa1 LIBOR + 0.775% — % LIBOR + 0.90% — % At Least BBB or Baa2 LIBOR + 0.85% — % LIBOR + 1.00% — % At Least BBB- or Baa3 LIBOR + 1.05% 0.05 % LIBOR + 1.25% 0.25 % Below BBB- or Baa3 LIBOR + 1.40% 0.40 % LIBOR + 1.65% 0.65 % The Credit Agreement contains financial covenants that, among other things, require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as covenants that may limit the Trust’s and the Operating Partnership’s ability to incur additional debt, grant liens, or make distributions. The Company may, at any time, voluntarily prepay any revolving or term loan under the Credit Agreement in whole or in part without premium or penalty. As of September 30, 2021, the Company was in compliance with all financial covenants related to the Credit Agreement. The Credit Agreement includes customary representations and warranties by the Trust and the Operating Partnership and imposes customary covenants on the Operating Partnership and the Trust. The Credit Agreement also contains customary events of default, and if an event of default occurs and continues, the Operating Partnership is subject to certain actions by the administrative agent, including without limitation, the acceleration of repayment of all amounts outstanding under the Credit Agreement. As of September 30, 2021, the Company had $159.0 million of borrowings outstanding under its unsecured revolving credit facility, and $250.0 million of borrowings outstanding under the term loan feature of the Credit Agreement. As defined by the Credit Agreement, the current unencumbered borrowing base allows the Company to borrow an additional $841.0 million before reaching the maximum allowed under the credit facility. Notes Payable As of September 30, 2021, the Company had $975.0 million aggregate principal amount of senior notes issued and outstanding by the Operating Partnership, comprised of $15.0 million maturing in 2023, $25.0 million maturing in 2025, $70.0 million maturing in 2026, $425.0 million maturing in 2027, $395.0 million maturing in 2028, and $45.0 million maturing in 2031. Certain properties have mortgage debt that contains financial covenants. As of September 30, 2021, the Trust was in compliance with all mortgage debt financial covenants. Scheduled principal payments due on consolidated debt as of September 30, 2021, are as follows (in thousands): 2021 $ 463 2022 20,825 2023 266,008 2024 23,669 2025 184,476 Thereafter 938,727 Total Payments $ 1,434,168 As of September 30, 2021, the Company had total consolidated indebtedness of approximately $1.4 billion. The weighted average interest rate on consolidated indebtedness was 3.48% (based on the 30-day LIBOR rate as of September 30, 2021, of 0.08%). For the three month periods ended September 30, 2021 and 2020, the Company incurred interest expense on its debt, exclusive of deferred financing cost amortization, of $12.9 million and $13.1 million, respectively. For the nine month periods ending September 30, 2021 and 2020, the Company incurred interest expense on its debt, exclusive of deferred financing cost amortization, of $39.0 million and $41.7 million, respectively. |
Derivatives
Derivatives | 9 Months Ended |
Sep. 30, 2021 | |
Derivative Instrument Detail [Abstract] | |
Derivatives | Derivatives In the normal course of business, a variety of financial instruments are used to manage or hedge interest rate risk. The Company has implemented ASC 815, Derivatives and Hedging (“ASC 815”), which establishes accounting and reporting standards requiring that all derivatives, including certain derivative instruments embedded in other contracts, be recorded as either an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception. When specific hedge accounting criteria are not met, ASC 815 requires that changes in a derivative’s fair value be recognized currently in earnings. Changes in the fair market values of the Company’s derivative instruments are recorded in the consolidated statements of income if such derivatives do not qualify for, or the Company does not elect to apply for, hedge accounting. As a result of the Company’s adoption of ASU 2017-12 as of January 1, 2019, the entire change in the fair value of its derivatives designated and qualified as cash flow hedges are recorded in accumulated other comprehensive income on the consolidated balance sheets and are subsequently reclassified into earnings in the period in which the hedged forecasted transaction affects earnings. To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of September 30, 2021, the Company had five outstanding interest rate swap contracts that are designated as cash flow hedges of interest rate risk. For presentational purposes, they are shown as one derivative due to the identical nature of their economic terms. See Note 2 (Summary of Significant Accounting Policies) of the 2020 Annual Report for a further discussion of our derivatives. The following table summarizes the location and aggregate fair value of the interest rate swaps on the Company’s consolidated balance sheets (in thousands): Total notional amount $ 250,000 Effective fixed interest rate (1) 2.07 % Effective date 7/7/2016 Maturity date 6/10/2023 Liability balance at September 30, 2021 (included in Accrued expenses and other liabilities) $ 3,567 Liability balance at December 31, 2020 (included in Accrued expenses and other liabilities) $ 5,317 |
Accrued Expenses and Other Liab
Accrued Expenses and Other Liabilities | 9 Months Ended |
Sep. 30, 2021 | |
Other Liabilities Disclosure [Abstract] | |
Accrued Expenses and Other Liabilities | Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following as of September 30, 2021 and December 31, 2020 (in thousands): September 30, December 31, Real estate taxes payable $ 27,033 $ 23,436 Prepaid rent 18,606 22,248 Accrued interest 5,746 16,009 Accrued expenses 5,619 5,721 Accrued incentive compensation 4,950 1,945 Security deposits 3,885 3,714 Interest rate swap 3,567 5,317 Tenant improvement allowances 1,857 1,917 Embedded derivative — 4,944 Other 8,358 6,678 Total $ 79,621 $ 91,929 |
Stock-based Compensation
Stock-based Compensation | 9 Months Ended |
Sep. 30, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Stock-based Compensation | Stock-based Compensation The Company follows ASC 718, Compensation - Stock Compensation (“ASC 718”), in accounting for its share-based payments. This guidance requires measurement of the cost of employee services received in exchange for stock compensation based on the grant-date fair value of the employee stock awards. This cost is recognized as compensation expense ratably over the employee’s requisite service period. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized when incurred. Share-based payments classified as liability awards are marked to fair value at each reporting period. Any common shares issued pursuant to the Company's incentive equity compensation and employee stock purchase plans will result in the Operating Partnership issuing OP Units to the Trust on a one-for-one basis, with the Operating Partnership receiving the net cash proceeds of such issuances. Certain of the Company’s employee stock awards vest only upon the achievement of performance targets. ASC 718 requires recognition of compensation cost only when achievement of performance conditions is considered probable. Consequently, the Company’s determination of the amount of stock compensation expense requires judgment in estimating the probability of achievement of these performance targets. Subsequent changes in actual experience are monitored and estimates are updated as information is available. In connection with the IPO, the Trust adopted the 2013 Equity Incentive Plan, which made shares available for awards for participants. On April 30, 2019, at the Annual Meeting of Shareholders of Physicians Realty Trust, the Trust’s shareholders approved the Amended and Restated Physicians Realty Trust 2013 Equity Incentive Plan (“2013 Plan”). The amendment increased the number of common shares authorized for issuance under the 2013 Plan to a total of 7,000,000 common shares authorized for issuance. The 2013 Plan term was also extended to 2029. Restricted Common Shares Restricted common shares granted under the 2013 Plan are eligible for dividends as well as the right to vote. In the nine month period ended September 30, 2021, the Trust granted a total of 224,163 restricted common shares with a total value of $3.9 million to its officers and certain of its employees, which have a vesting period of one A summary of the status of the Trust’s non-vested restricted common shares as of September 30, 2021 and changes during the nine month period then ended follow: Common Shares Weighted Non-vested at December 31, 2020 215,822 $ 18.73 Granted 224,163 17.42 Vested (185,968) 18.94 Non-vested at September 30, 2021 254,017 $ 17.42 For all service awards, the Company records compensation expense for the entire award on a straight-line basis over the requisite service period. For the three month periods ending September 30, 2021 and 2020, the Company recognized non-cash share compensation of $1.0 million and $0.9 million, respectively. For the nine month periods ending September 30, 2021 and 2020, the Company recognized non-cash share compensation of $2.8 million and $2.6 million, respectively. Unrecognized compensation expense at September 30, 2021 was $2.4 million. Restricted Share Units In January 2021, under the 2013 Plan, the Company granted 13,343 restricted share units to certain of its trustees in lieu of all or a portion of such trustee’s 2021 cash retainer. These units are subject to certain timing conditions and a one-year service period. Each restricted share unit contains one dividend equivalent. Each recipient will accrue dividend equivalents on awarded share units equal to the cash dividend that would have been paid on the awarded share unit had the awarded share unit been an issued and outstanding common share on the record date for the dividend. With respect to the performance and timing conditions of the January 2021 grants, the grant date fair value of $17.80 per unit was based on the share price at the date of grant. In March 2021, under the 2013 Plan, the Company granted restricted share units at a target level of 265,275 to its officers and certain of its employees and 43,582 to its trustees. Units granted to officers and certain employees under the Company’s 2013 Plan are subject to certain performance and market conditions and a three-year service period. Units granted to trustees are subject to certain timing conditions and a two-year service period. Each restricted share unit contains one dividend equivalent. Each recipient will accrue dividend equivalents on awarded share units equal to the cash dividend that would have been paid on the awarded share unit had the awarded share unit been an issued and outstanding common share on the record date for the dividend. Approximately 40% of the restricted share units issued to officers and certain employees under the Company’s 2013 Plan in 2021 vest based on two certain market conditions. The awards containing market conditions were valued with the assistance of independent valuation specialists. The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair values of $27.53 and $30.82 per unit for the March 2021 grant using the following assumptions: Volatility 33.3 % Dividend assumption reinvested Expected term in years 2.84 years Risk-free rate 0.25 % Share price (per share) $ 17.21 The remaining 60% of the restricted share units issued to officers and certain employees under the Company’s 2013 Plan, and 100% of other restricted share units issued to trustees vest based upon certain performance or timing conditions. With respect to the performance and timing conditions of the March 2021 grants, the grant date fair value of $17.21 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2021 restricted share units issued to officers and certain employees is $22.00 per unit. The following is a summary of the activity in the Trust’s restricted share units during the nine months ended September 30, 2021: Executive Awards Trustee Awards Restricted Share Weighted Restricted Share Weighted Non-vested at December 31, 2020 964,139 $ 21.17 59,820 $ 18.81 Granted 265,275 22.00 56,925 17.35 Vested (252,844) (1) 16.58 (40,394) 18.57 Non-vested at September 30, 2021 976,570 $ 22.59 76,351 $ 17.84 (1) Restricted units vested by Company executives in 2021 resulted in the issuance of 399,165 common shares, less 162,173 common shares withheld to cover minimum withholding tax obligations, for multiple employees. For the three month periods ending September 30, 2021 and 2020, the Company recognized non-cash share compensation expense of $2.7 million and $2.2 million, respectively. For the nine month periods ending September 30, 2021 and 2020, the Company recognized non-cash share compensation of $8.0 million and $6.5 million, respectively. Unrecognized compensation expense at September 30, 2021 was $12.7 million. |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Sep. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements ASC Topic 820, Fair Value Measurement (“ASC 820”), requires certain assets and liabilities be reported and/or disclosed at fair value in the financial statements and provides a framework for establishing that fair value. The framework for determining fair value is based on a hierarchy that prioritizes the valuation techniques and inputs used to measure fair value. In general, fair values determined by Level 1 inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Fair values determined by Level 2 inputs use other inputs that are observable, either directly or indirectly. These Level 2 inputs include quoted prices for similar assets and liabilities in active markets, and other inputs such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset. These Level 3 fair value measurements are based primarily on management’s own estimates using pricing models, discounted cash flow methodologies, or similar techniques taking into account the characteristics of the asset or liability. In instances where inputs used to measure fair value fall into different levels of the fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. As part of the Company’s acquisition process, Level 3 inputs are used to measure the fair value of the assets acquired and liabilities assumed. The Company’s derivative instruments as of September 30, 2021 consist of five interest rate swaps. For presentational purposes, the Company’s interest rate swaps are shown as a single derivative due to the identical nature of their economic terms, as detailed in the Derivative Instruments section of Note 7 (Derivatives) of this report and Note 2 (Summary of Significant Accounting Policies) of Part II, Item 8 (Financial Statements and Supplementary Data) of our 2020 Annual Report. The interest rate swaps are not traded on an exchange. The Company’s derivative assets and liabilities are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis. The fair values are based on Level 2 inputs described above. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivatives. The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This generally includes assets subject to impairment. There was one asset measured at fair value as of September 30, 2021 that had a previous carrying value of $2.3 million. During the three and nine months ended September 30, 2021, the Company recorded an impairment charge of $0.3 million against the asset, a medical office building located in Michigan that is currently classified as held for sale. The carrying amounts of cash and cash equivalents, tenant receivables, payables, and accrued interest are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for real estate loans receivable and mortgage debt are estimated based on rates currently prevailing for similar instruments of similar maturities and are based primarily on Level 2 inputs. As of September 30, 2021, the Company classified four properties, as held for sale. Upon classification as held for sale, the Company records the value of the assets at the lower of their carrying value or fair value, less costs to sell. Fair value is generally based on discounted cash flow analyses, which involves management’s best estimate of market participants’ holding period, market comparables, future occupancy levels, rental rates, capitalization rates, lease-up periods, and capital requirements. As of September 30, 2021, the fair value exceeds the carrying value of the four assets classified as held for sale and therefore, are recorded at respective carrying value. The following table presents the fair value of the Company’s financial instruments (in thousands): September 30, 2021 December 31, 2020 Carrying Fair Carrying Fair Assets: Real estate loans receivable, net $ 181,125 $ 177,859 $ 198,800 $ 198,814 Notes receivable, net $ 1,045 $ 1,045 $ 23,760 $ 23,760 Liabilities: Credit facility $ (409,000) $ (409,000) $ (416,000) $ (416,000) Notes payable $ (975,000) $ (1,066,869) $ (975,000) $ (1,063,367) Mortgage debt $ (50,194) $ (51,458) $ (58,074) $ (59,651) Derivative liabilities $ (3,567) $ (3,567) $ (10,261) $ (10,261) |
Tenant Operating Leases
Tenant Operating Leases | 9 Months Ended |
Sep. 30, 2021 | |
Leases [Abstract] | |
Tenant Operating Leases | Tenant Operating Leases The Company is a lessor of medical office buildings and other health care facilities. Leases have expirations from 2021 through 2043. As of September 30, 2021, the future minimum rental payments on non-cancelable leases, exclusive of expense recoveries and minimum rental payments for the four assets classified as held for sale, were as follows (in thousands): 2021 $ 77,498 2022 305,188 2023 297,695 2024 285,362 2025 269,862 Thereafter 961,607 Total $ 2,197,212 For the three month periods ending September 30, 2021 and 2020, we recognized $110.3 million and $104.4 million, respectively, of rental and other lease-related income related to our operating leases, of which $29.2 million and $26.3 million, respectively, were variable lease payments. For the nine month periods ending September 30, 2021 and 2020, we recognized $326.0 million and $311.9 million, respectively, of rental and other leased-related income related to our operating leases, of which $84.0 million and $76.1 million, respectively, were variable lease payments. |
Rent Expense
Rent Expense | 9 Months Ended |
Sep. 30, 2021 | |
Leases [Abstract] | |
Rent Expense | Rent Expense The Company leases the rights to parking structures at two of its properties, the air space above one property, and the land upon which 82 of its properties are located from third party land owners pursuant to separate leases. In addition, the Company has nine corporate leases, primarily for office space. The Company’s leases include both fixed and variable rental payments and may also include escalation clauses and renewal options. These leases have terms of up to 86 years remaining, excluding extension options, with a weighted average remaining term of 43 years. At the inception of a new lease, the Company establishes an operating or finance lease asset and operating or finance lease liability calculated as the present value of future minimum lease payments. As our leases do not provide an implicit rate, we calculate a discount rate that approximates our incremental borrowing rate available at lease commencement to determine the present value of future minimum lease payments. The approximated weighted average discount rate was 4.4% as of September 30, 2021. There are no operating or finance leases that have not yet commenced that would have a significant impact on the Company’s consolidated balance sheets. As of September 30, 2021, the future minimum lease obligations under non-cancelable parking, air, ground, and corporate leases, exclusive of the four assets classified as held for sale, were as follows (in thousands): 2021 $ 849 2022 3,719 2023 3,693 2024 3,676 2025 3,657 Thereafter 180,378 Total undiscounted lease payments $ 195,972 Less: Interest (117,290) Present value of lease liabilities $ 78,682 Lease costs consisted of the following for the nine months ended September 30, 2021 (in thousands): Fixed lease cost $ 1,823 Variable lease cost 751 Total lease cost $ 2,574 |
Credit Concentration
Credit Concentration | 9 Months Ended |
Sep. 30, 2021 | |
Concentration Risks, Types, No Concentration Percentage [Abstract] | |
Credit Concentration | Credit Concentration The Company uses annualized base rent (“ABR”) as its credit concentration metric. ABR is calculated by multiplying contractual base rent for the month ended September 30, 2021 by 12, excluding the impact of concessions and straight-line rent. The following table summarizes certain information about the Company’s top five tenant credit concentrations as of September 30, 2021, excluding the four assets classified as held for sale (in thousands): Tenant Total ABR Percent of ABR CommonSpirit - CHI - Nebraska $ 17,656 5.7 % Northside Hospital 15,245 4.9 % UofL Health - Louisville, Inc. 12,526 4.1 % US Oncology 11,080 3.6 % Baylor Scott and White Health 8,156 2.6 % Remaining portfolio 244,512 79.1 % Total $ 309,175 100.0 % ABR collected from the Company’s top five tenant relationships comprises 20.9% of its total ABR for the period ending September 30, 2021. Total ABR from CommonSpirit Health affiliated tenants totals 16.5%, including the affiliates disclosed above. The following table summarizes certain information about the Company’s top five geographic concentrations as of September 30, 2021, excluding the four assets classified as held for sale (in thousands): State Total ABR Percent of ABR Texas $ 47,331 15.3 % Georgia 25,618 8.3 % Indiana 22,784 7.4 % Nebraska 18,993 6.1 % Minnesota 17,827 5.8 % Other 176,622 57.1 % Total $ 309,175 100.0 % |
Earnings Per Share
Earnings Per Share | 9 Months Ended |
Sep. 30, 2021 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share The following table shows the amounts used in computing the Trust’s basic and diluted earnings per share (in thousands, except share and per share data): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Numerator for earnings per share - basic: Net income $ 22,045 $ 16,475 $ 58,531 $ 49,879 Net income attributable to noncontrolling interests: Operating Partnership (529) (425) (1,405) (1,305) Partially owned properties (152) (151) (455) (441) Preferred distributions — (317) (13) (951) Numerator for earnings per share - basic $ 21,364 $ 15,582 $ 56,658 $ 47,182 Numerator for earnings per share - diluted: Numerator for earnings per share - basic $ 21,364 $ 15,582 $ 56,658 $ 47,182 Operating Partnership net income 529 425 1,405 1,305 Numerator for earnings per share - diluted $ 21,893 $ 16,007 $ 58,063 $ 48,487 Denominator for earnings per share - basic and diluted: Weighted average number of shares outstanding - basic 217,406,657 208,187,129 214,616,482 202,717,190 Effect of dilutive securities: Noncontrolling interest - Operating Partnership units 5,406,070 5,643,669 5,498,046 5,655,870 Restricted common shares 98,597 70,819 95,999 72,522 Restricted share units 1,080,725 1,228,351 1,189,122 1,109,478 Denominator for earnings per share - diluted: 223,992,049 215,129,968 221,399,649 209,555,060 Earnings per share - basic $ 0.10 $ 0.07 $ 0.26 $ 0.23 Earnings per share - diluted $ 0.10 $ 0.07 $ 0.26 $ 0.23 |
Subsequent Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent EventsSince September 30, 2021, the Company issued 2,877,988 shares pursuant to its 2021 ATM program at a weighted average price of $18.61 for net proceeds of $53.0 million. On October 1, 2021, the Company entered into a master transaction agreement with Landmark Healthcare Companies LLC to acquire 15 medical office buildings located in eight states (the “Landmark Portfolio”) for an aggregate purchase price of $764.3 million, subject to closing prorations and other adjustments. Subject to the satisfaction of certain conditions to closing, the Company expects to complete the acquisition of the Landmark Portfolio in the fourth quarter of 2021. There can be no assurance that any or all of the conditions to closing will be satisfied or, if satisfied, that the Company will complete the acquisition of the Landmark Portfolio in a timely manner or at all. On October 13, 2021, the Operating Partnership issued and sold $500.0 million aggregate principal amount of 2.625% senior notes, which will mature on November 1, 2031. The senior notes were sold at an issue price of 99.789% of their face value, before the underwriters’ discount. The Company’s net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $495.1 million. On October 13, 2021, the Company used the proceeds from the senior notes to pay off the existing balance of the unsecured revolving credit facility and the term loan feature of the Credit Agreement for $168.0 million and $250.0 million, respectively. The Operating Partnership simultaneously terminated the existing pay-fixed receive-variable rate swaps associated with the full term loan borrowing of $250.0 million. As part of the termination, the Company made total cash payments of $3.3 million to the counterparties of the swap agreements. On October 15, 2021, the Company completed the acquisition of the remaining 51% membership interest in MedCore Realty Eden Hill, LLC for approximately $33.2 million. This joint venture owns a 140,205 square foot medical office facility located in Dover, Delaware. On October 27, 2021, the Company completed the acquisition of a newly completed 109,423 square foot medical office facility located in Scottsdale, Arizona for a purchase price of approximately $67.3 million. On November 2, 2021, the Company sold the LifeCare portfolio, which included three long-term acute care hospital (“LTACH”) properties, for approximately $62.0 million and recognized a net gain on the sale of approximately $18.7 million. These assets were also classified as held for sale as of September 30, 2021. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Policies [Abstract] | |
Noncontrolling Interests | Noncontrolling Interests As of September 30, 2021, the Trust held a 97.6% interest in the Operating Partnership. As the sole general partner and the majority interest holder, the Trust consolidates the financial position and results of operations of the Operating Partnership. |
Tax Status of Dividends and Distributions | Tax Status of Dividends and Distributions The Company’s distributions of current and accumulated earnings and profits for U.S. federal income tax purposes generally are taxable to shareholders as ordinary income. Distributions in excess of these earnings and profits generally are treated as a non-taxable reduction of the shareholders’ basis in the shares to the extent thereof (non-dividend distributions) and thereafter as taxable gain. Any cash distributions received by an OP Unit holder in respect of its OP Units generally will not be taxable to such OP Unit holder for U.S. federal income tax purposes, to the extent that such distribution does not exceed the OP Unit holder’s basis in its OP Units. Any such distribution will instead reduce the OP Unit holder’s basis in its OP Units (and OP Unit holders will be subject to tax on the taxable income allocated to them by the Operating Partnership in respect of their OP Units when such income is earned by the Operating Partnership, with such income allocation increasing the OP Unit holders’ basis in their OP Units). |
Impairment of Intangible and Long-Lived Assets | Impairment of Intangible and Long-Lived AssetsThe Company periodically evaluates its long-lived assets, primarily consisting of investments in real estate, for impairment indicators or whenever events or changes in circumstances indicate that the recorded amount of an asset may not be fully recoverable. |
Assets Held for Sale | Assets Held for Sale The Company may sell properties from time to time for various reasons, including favorable market conditions. The Company classifies certain long-lived assets as held for sale once the criteria, as defined by GAAP, have been met. The Company classifies a real estate property as held for sale when: (i) management has approved the disposition of the property, (ii) the property is available for sale in its present condition, (iii) an active program to locate a buyer has been initiated, (iv) it is probable that the property will be disposed of within one year, (v) the property is being marketed at a reasonable price relative to its fair value, and (vi) it is unlikely that the disposition plan will significantly change or be withdrawn. Following the classification of a property as “held for sale,” no further depreciation or amortization is recorded for the asset and the book value of the asset is written down to the lower of carrying value or fair market value, less cost to sell . |
Real Estate Loans Receivable, Net | Real Estate Loans Receivable, Net |
Rental and Related Revenues | Rental and Related Revenues Rental revenue is recognized on a straight-line basis over the terms of the related leases when collectability is probable. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue for amounts more or less than amounts currently due from tenants. Amounts recognized in excess of amounts currently due from tenants, excluding assets classified as held for sale, are included in other assets and were approximately $93.7 million and $86.6 million as of September 30, 2021 and December 31, 2020, respectively. If the Company determines that collectability of straight-line rents is not probable, income recognition is limited to the lesser of cash collected, or lease income reflected on a straight-line basis, plus variable rent when it becomes accruable. In accordance with ASC 842, Leases , if the collectability of a lease changes after the commencement date, any difference between lease income that would have been recognized and the lease payments shall be recognized as an adjustment to lease income. Bad debt recognized as an adjustment to rental and related revenues was insignificant for the three and nine months ended September 30, 2021. Bad debt recognized as an adjustment to rental and related revenues was $0.4 million and $0.5 million for the three and nine months ended September 30, 2020, respectively. Rental revenue is adjusted by the amortization of lease inducements and above-market or below-market rents on certain leases. Lease inducements and above-market or below-market rents are amortized on a straight-line basis over the remaining lease term. Rental and related revenues also include expense recoveries, which relate to tenant reimbursement of real estate taxes, insurance, and other operating expenses that are recognized in the period the applicable expenses are incurred. The reimbursements are recorded gross, as the Company is generally the primary obligor with respect to real estate taxes and purchasing goods and services from third-party suppliers, has discretion in selecting the supplier, and bears the credit risk of tenant reimbursement. |
New Accounting Pronouncements | New Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which changes the impairment model for most financial instruments by requiring companies to recognize an allowance for expected losses, rather than incur losses as required previously by the other-than-temporary impairment model. ASU 2016-13 applies to most financial assets measured at amortized cost and certain other instruments, including certain receivables, loans, held-to-maturity debt securities, net investments in leases, and off-balance-sheet credit exposures (e.g., loan commitments). ASU 2016-13 requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected through an allowance for credit losses that is deducted from the amortized cost basis. ASU 2018-19 also clarifies that receivables arising from operating leases are not within the scope of Subtopic 326-20. Instead, impairment of these receivables should be accounted for in accordance with ASC 842. The Company has adopted ASU 2016-13 as of the effective date, January 1, 2020, with a cumulative effect adjustment to the opening balance of retained earnings of $0.1 million. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting , that provides optional relief to applying reference rate reform to changing reference rates, contracts, hedging relationships, and other transactions that reference LIBOR, which will be discontinued by the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. The Company is evaluating how the transition away from LIBOR will impact the Company, and if the optional relief in this standard will be adopted. The Company does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements if adopted. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) , which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, with early adoption permitted. The Company is currently evaluating the impact ASU 2020-06 will have on its consolidated financial statements. |
Derivatives | In the normal course of business, a variety of financial instruments are used to manage or hedge interest rate risk. The Company has implemented ASC 815, Derivatives and Hedging (“ASC 815”), which establishes accounting and reporting standards requiring that all derivatives, including certain derivative instruments embedded in other contracts, be recorded as either an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception. When specific hedge accounting criteria are not met, ASC 815 requires that changes in a derivative’s fair value be recognized currently in earnings. Changes in the fair market values of the Company’s derivative instruments are recorded in the consolidated statements of income if such derivatives do not qualify for, or the Company does not elect to apply for, hedge accounting. As a result of the Company’s adoption of ASU 2017-12 as of January 1, 2019, the entire change in the fair value of its derivatives designated and qualified as cash flow hedges are recorded in accumulated other comprehensive income on the consolidated balance sheets and are subsequently reclassified into earnings in the period in which the hedged forecasted transaction affects earnings. To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of September 30, 2021, the Company had five outstanding interest rate swap contracts that are designated as cash flow hedges of interest rate risk. For presentational purposes, they are shown as one derivative due to the identical nature of their economic terms. See Note 2 (Summary of Significant Accounting Policies) of the 2020 Annual Report for a further discussion of our derivatives. |
Fair Value Measurements | The Company’s derivative instruments as of September 30, 2021 consist of five interest rate swaps. For presentational purposes, the Company’s interest rate swaps are shown as a single derivative due to the identical nature of their economic terms, as detailed in the Derivative Instruments section of Note 7 (Derivatives) of this report and Note 2 (Summary of Significant Accounting Policies) of Part II, Item 8 (Financial Statements and Supplementary Data) of our 2020 Annual Report. The interest rate swaps are not traded on an exchange. The Company’s derivative assets and liabilities are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis. The fair values are based on Level 2 inputs described above. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivatives. The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This generally includes assets subject to impairment. There was one asset measured at fair value as of September 30, 2021 that had a previous carrying value of $2.3 million. During the three and nine months ended September 30, 2021, the Company recorded an impairment charge of $0.3 million against the asset, a medical office building located in Michigan that is currently classified as held for sale. The carrying amounts of cash and cash equivalents, tenant receivables, payables, and accrued interest are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for real estate loans receivable and mortgage debt are estimated based on rates currently prevailing for similar instruments of similar maturities and are based primarily on Level 2 inputs. As of September 30, 2021, the Company classified four properties, as held for sale. Upon classification as held for sale, the Company records the value of the assets at the lower of their carrying value or fair value, less costs to sell. Fair value is generally based on discounted cash flow analyses, which involves management’s best estimate of market participants’ holding period, market comparables, future occupancy levels, rental rates, capitalization rates, lease-up periods, and capital requirements. As of September 30, 2021, the fair value exceeds the carrying value of the four assets classified as held for sale and therefore, are recorded at respective carrying value. |
Stock-based Compensation | The Company follows ASC 718, Compensation - Stock Compensation (“ASC 718”), in accounting for its share-based payments. This guidance requires measurement of the cost of employee services received in exchange for stock compensation based on the grant-date fair value of the employee stock awards. This cost is recognized as compensation expense ratably over the employee’s requisite service period. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized when incurred. Share-based payments classified as liability awards are marked to fair value at each reporting period. Any common shares issued pursuant to the Company's incentive equity compensation and employee stock purchase plans will result in the Operating Partnership issuing OP Units to the Trust on a one-for-one basis, with the Operating Partnership receiving the net cash proceeds of such issuances. Certain of the Company’s employee stock awards vest only upon the achievement of performance targets. ASC 718 requires recognition of compensation cost only when achievement of performance conditions is considered probable. Consequently, the Company’s determination of the amount of stock compensation expense requires judgment in estimating the probability of achievement of these performance targets. Subsequent changes in actual experience are monitored and estimates are updated as information is available. |
Organization and Business (Tabl
Organization and Business (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of Sale or Issuance of Common Stock | During the quarterly periods ended March 31, 2021, June 30, 2021, and September 30, 2021, the Trust’s issuance and sale of common shares pursuant to the ATM Programs is as follows (in thousands, except common shares and price): Common Weighted average price Net Quarterly period ended March 31, 2021 2,887,296 $ 18.32 $ 52,358 Quarterly period ended June 30, 2021 4,532,343 18.39 82,519 Quarterly period ended September 30, 2021 — — — Year to date 7,419,639 $ 18.36 $ 134,877 |
Investment and Disposition Ac_2
Investment and Disposition Activity (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Business Combination and Asset Acquisition [Abstract] | |
Asset Acquisition | Investment activity for the three months ended September 30, 2021 is summarized below: Investment (1) Location Acquisition Investment Amount InterMed MOB - Davis Joint Venture (2) Portland, ME August 18, 2021 $ 7,291 Atkins Portfolio (5 MOBs) Various August 30, 2021 54,090 HonorHealth - Sonoran MOB Phoenix, AZ September 23, 2021 31,750 Loan Investments Various Various 3,734 $ 96,865 (1) “MOB” means medical office building (2) The Company purchased a 49% membership interest in this property through the Davis Joint Venture. The following table summarizes the acquisition date fair values of the assets acquired and the liabilities assumed during the nine months ended September 30, 2021, which the Company determined using Level 2 and Level 3 inputs (in thousands): 1st Quarter 2nd Quarter 3rd Quarter Total Land $ 189 $ 2,655 $ 8,054 $ 10,898 Building and improvements 917 44,743 66,652 112,312 In-place lease intangibles 29 4,442 8,216 12,687 Above market in-place lease intangibles — — 241 241 Below market in-place lease intangibles — — (151) (151) Right-of-use asset — — 1,700 1,700 Prepaid expenses — 129 — 129 Net assets acquired $ 1,135 $ 51,969 $ 84,712 $ 137,816 |
Disposal Groups, Including Discontinued Operations | Assets Held for Sale As of September 30, 2021, the Company classified four assets as held for sale. In accordance with this classification, the following assets are classified as held for sale in the accompanying consolidated balance sheets at September 30, 2021 (in thousands). Land and improvements $ 7,660 Building and improvements 49,930 Tenant improvements 455 Acquired lease intangibles 3,141 Real estate held for sale before accumulated depreciation 61,186 Accumulated depreciation (16,480) Real estate held for sale $ 44,706 |
Intangibles (Tables)
Intangibles (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Finite-Lived Intangible Assets, Net [Abstract] | |
Summary of the carrying amount of intangible assets and liabilities | The following is a summary of the carrying amount of intangible assets and liabilities, excluding assets classified as held for sale if applicable, as of September 30, 2021 and December 31, 2020 (in thousands): September 30, 2021 December 31, 2020 Cost Accumulated Net Cost Accumulated Net Assets In-place leases $ 364,750 $ (193,231) $ 171,519 $ 362,837 $ (173,862) $ 188,975 Above-market leases $ 43,586 $ (23,373) $ 20,213 $ 43,386 $ (20,670) $ 22,716 Leasehold interest $ 712 $ (406) $ 306 $ 712 $ (361) $ 351 Liabilities Below-market leases $ 15,980 $ (10,151) $ 5,829 $ 15,882 $ (9,241) $ 6,641 |
Summary of the carrying amount of acquired lease intangibles | The following is a summary of acquired lease intangible amortization for the three and nine month periods ended September 30, 2021 and 2020 (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Amortization expense related to in-place leases $ 8,103 $ 9,088 $ 24,590 $ 26,190 Decrease in rental income related to above-market leases 897 954 2,744 2,918 Decrease in rental income related to leasehold interest 15 15 45 45 Increase in rental income related to below-market leases 324 397 963 1,102 |
Schedule of future amortization of the acquired lease intangibles | Future aggregate net amortization of acquired lease intangibles, excluding four assets classified as held for sale, as of September 30, 2021, is as follows (in thousands): Net Decrease in Net Increase in 2021 $ 547 $ 7,954 2022 1,963 29,276 2023 1,656 26,546 2024 1,589 23,350 2025 1,590 19,817 Thereafter 7,345 64,576 Total $ 14,690 $ 171,519 |
Other Assets (Tables)
Other Assets (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Other Assets, Unclassified [Abstract] | |
Schedule of other assets | Other assets consisted of the following, excluding assets classified as held for sale if applicable, as of September 30, 2021 and December 31, 2020 (in thousands): September 30, December 31, Straight line rent receivable, net $ 93,747 $ 86,551 Leasing commissions, net 11,441 9,282 Prepaid expenses 8,943 9,401 Lease inducements, net 8,518 9,396 Escrows 1,546 1,507 Notes receivable, net 1,045 23,760 Other 5,249 4,103 Total $ 130,489 $ 144,000 |
Debt (Tables)
Debt (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of debt | The following is a summary of debt as of September 30, 2021 and December 31, 2020 (in thousands): September 30, December 31, Fixed interest mortgage notes (1) $ 44,420 $ 51,896 Variable interest mortgage note (2) 5,748 6,105 Total mortgage debt 50,168 58,001 Unsecured revolving credit facility bearing variable interest (3) 159,000 166,000 $400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027 400,000 400,000 $350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028 350,000 350,000 $250 million unsecured term borrowing bearing fixed interest of 2.07%, due June 2023 (4) 250,000 250,000 $150 million senior unsecured notes bearing fixed interest of 4.03% to 4.74%, due January 2023 to 2031 150,000 150,000 $75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027 75,000 75,000 Total principal 1,434,168 1,449,001 Unamortized deferred financing costs (8,925) (5,369) Unamortized discounts (4,366) (4,855) Unamortized fair value adjustments 26 73 Total debt $ 1,420,903 $ 1,438,850 (1) As of September 30, 2021, fixed interest mortgage notes bear interest from 4.63% to 5.50%, due in 2022 and 2024, with a weighted average interest rate of 4.79%. As of December 31, 2020, fixed interest mortgage notes bear interest from 4.63% to 5.50%, due in 2021, 2022, and 2024, with a weighted average interest rate of 4.78%. The notes are collateralized by three properties with a net book value of $97.0 million as of September 30, 2021 and four properties with a net book value of $110.3 million as of December 31, 2020. (2) Variable interest mortgage note bears variable interest of LIBOR plus 2.75%, for an interest rate of 2.83% and 2.90% as of September 30, 2021 and December 31, 2020, respectively. The note is due in 2028 and is collateralized by one property with a net book value of $8.1 million as of September 30, 2021 and $8.3 million as of December 31, 2020. (3) As of September 30, 2021, the amount of commitments under the revolving credit facility was $1.0 billion bearing variable interest of LIBOR plus 0.85%, due September 2025. As of December 31, 2020, the amount of commitments under the revolving credit facility was $850.0 million bearing variable interest of LIBOR plus 0.90%, due September 2022. (4) The Operating Partnership’s borrowings under the term loan feature of the Credit Agreement bears interest at a rate which is determined by the Trust’s credit rating, currently equal to LIBOR + 1.00%. The Operating Partnership has entered into a pay-fixed receive-variable interest rate swap, fixing the LIBOR component of this rate at 1.07%. |
Schedule of adjusted LIBOR rate loans and interest rates based on credit rating | Base Rate Loans, Adjusted LIBOR Rate Loans, and Letters of Credit (each, as defined in the Credit Agreement) will be subject to interest rates, based upon the Trust’s investment grade rating as follows: Credit Rating Applicable Margin for Revolving Loans: LIBOR Rate Loans Applicable Margin for Revolving Loans: Base Rate Loans Applicable Margin for Term Loans: LIBOR Rate Loans Applicable Margin for Term Loans: Base Rate Loans At Least A- or A3 LIBOR + 0.725% — % LIBOR + 0.85% — % At Least BBB+ or Baa1 LIBOR + 0.775% — % LIBOR + 0.90% — % At Least BBB or Baa2 LIBOR + 0.85% — % LIBOR + 1.00% — % At Least BBB- or Baa3 LIBOR + 1.05% 0.05 % LIBOR + 1.25% 0.25 % Below BBB- or Baa3 LIBOR + 1.40% 0.40 % LIBOR + 1.65% 0.65 % |
Schedule of principal payments due on debt | Scheduled principal payments due on consolidated debt as of September 30, 2021, are as follows (in thousands): 2021 $ 463 2022 20,825 2023 266,008 2024 23,669 2025 184,476 Thereafter 938,727 Total Payments $ 1,434,168 |
Derivatives (Tables)
Derivatives (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Derivative Instrument Detail [Abstract] | |
Schedule of interest rate derivatives | The following table summarizes the location and aggregate fair value of the interest rate swaps on the Company’s consolidated balance sheets (in thousands): Total notional amount $ 250,000 Effective fixed interest rate (1) 2.07 % Effective date 7/7/2016 Maturity date 6/10/2023 Liability balance at September 30, 2021 (included in Accrued expenses and other liabilities) $ 3,567 Liability balance at December 31, 2020 (included in Accrued expenses and other liabilities) $ 5,317 |
Accrued Expenses and Other Li_2
Accrued Expenses and Other Liabilities (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Other Liabilities Disclosure [Abstract] | |
Schedule of accrued expenses and other liabilities | Accrued expenses and other liabilities consisted of the following as of September 30, 2021 and December 31, 2020 (in thousands): September 30, December 31, Real estate taxes payable $ 27,033 $ 23,436 Prepaid rent 18,606 22,248 Accrued interest 5,746 16,009 Accrued expenses 5,619 5,721 Accrued incentive compensation 4,950 1,945 Security deposits 3,885 3,714 Interest rate swap 3,567 5,317 Tenant improvement allowances 1,857 1,917 Embedded derivative — 4,944 Other 8,358 6,678 Total $ 79,621 $ 91,929 |
Stock-based Compensation (Table
Stock-based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of non-vested restricted common shares | A summary of the status of the Trust’s non-vested restricted common shares as of September 30, 2021 and changes during the nine month period then ended follow: Common Shares Weighted Non-vested at December 31, 2020 215,822 $ 18.73 Granted 224,163 17.42 Vested (185,968) 18.94 Non-vested at September 30, 2021 254,017 $ 17.42 |
Schedule of weighted average grant date fair value assumptions | The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair values of $27.53 and $30.82 per unit for the March 2021 grant using the following assumptions: Volatility 33.3 % Dividend assumption reinvested Expected term in years 2.84 years Risk-free rate 0.25 % Share price (per share) $ 17.21 |
Summary of the activity in the restricted share units | The following is a summary of the activity in the Trust’s restricted share units during the nine months ended September 30, 2021: Executive Awards Trustee Awards Restricted Share Weighted Restricted Share Weighted Non-vested at December 31, 2020 964,139 $ 21.17 59,820 $ 18.81 Granted 265,275 22.00 56,925 17.35 Vested (252,844) (1) 16.58 (40,394) 18.57 Non-vested at September 30, 2021 976,570 $ 22.59 76,351 $ 17.84 (1) Restricted units vested by Company executives in 2021 resulted in the issuance of 399,165 common shares, less 162,173 common shares withheld to cover minimum withholding tax obligations, for multiple employees. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Schedule of fair value of other financial instruments | The following table presents the fair value of the Company’s financial instruments (in thousands): September 30, 2021 December 31, 2020 Carrying Fair Carrying Fair Assets: Real estate loans receivable, net $ 181,125 $ 177,859 $ 198,800 $ 198,814 Notes receivable, net $ 1,045 $ 1,045 $ 23,760 $ 23,760 Liabilities: Credit facility $ (409,000) $ (409,000) $ (416,000) $ (416,000) Notes payable $ (975,000) $ (1,066,869) $ (975,000) $ (1,063,367) Mortgage debt $ (50,194) $ (51,458) $ (58,074) $ (59,651) Derivative liabilities $ (3,567) $ (3,567) $ (10,261) $ (10,261) |
Tenant Operating Leases (Tables
Tenant Operating Leases (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Leases [Abstract] | |
Lessor, operating lease, payments to be received, maturity | As of September 30, 2021, the future minimum rental payments on non-cancelable leases, exclusive of expense recoveries and minimum rental payments for the four assets classified as held for sale, were as follows (in thousands): 2021 $ 77,498 2022 305,188 2023 297,695 2024 285,362 2025 269,862 Thereafter 961,607 Total $ 2,197,212 |
Rent Expense (Tables)
Rent Expense (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Leases [Abstract] | |
Schedule of future minimum lease obligations under non-cancelable ground leases | As of September 30, 2021, the future minimum lease obligations under non-cancelable parking, air, ground, and corporate leases, exclusive of the four assets classified as held for sale, were as follows (in thousands): 2021 $ 849 2022 3,719 2023 3,693 2024 3,676 2025 3,657 Thereafter 180,378 Total undiscounted lease payments $ 195,972 Less: Interest (117,290) Present value of lease liabilities $ 78,682 |
Lease cost | Lease costs consisted of the following for the nine months ended September 30, 2021 (in thousands): Fixed lease cost $ 1,823 Variable lease cost 751 Total lease cost $ 2,574 |
Credit Concentration (Tables)
Credit Concentration (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Concentration Risks, Types, No Concentration Percentage [Abstract] | |
Schedules of concentration of risk, by risk factor | The following table summarizes certain information about the Company’s top five tenant credit concentrations as of September 30, 2021, excluding the four assets classified as held for sale (in thousands): Tenant Total ABR Percent of ABR CommonSpirit - CHI - Nebraska $ 17,656 5.7 % Northside Hospital 15,245 4.9 % UofL Health - Louisville, Inc. 12,526 4.1 % US Oncology 11,080 3.6 % Baylor Scott and White Health 8,156 2.6 % Remaining portfolio 244,512 79.1 % Total $ 309,175 100.0 % The following table summarizes certain information about the Company’s top five geographic concentrations as of September 30, 2021, excluding the four assets classified as held for sale (in thousands): State Total ABR Percent of ABR Texas $ 47,331 15.3 % Georgia 25,618 8.3 % Indiana 22,784 7.4 % Nebraska 18,993 6.1 % Minnesota 17,827 5.8 % Other 176,622 57.1 % Total $ 309,175 100.0 % |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of amounts used in computing basic and diluted earnings per share | The following table shows the amounts used in computing the Trust’s basic and diluted earnings per share (in thousands, except share and per share data): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Numerator for earnings per share - basic: Net income $ 22,045 $ 16,475 $ 58,531 $ 49,879 Net income attributable to noncontrolling interests: Operating Partnership (529) (425) (1,405) (1,305) Partially owned properties (152) (151) (455) (441) Preferred distributions — (317) (13) (951) Numerator for earnings per share - basic $ 21,364 $ 15,582 $ 56,658 $ 47,182 Numerator for earnings per share - diluted: Numerator for earnings per share - basic $ 21,364 $ 15,582 $ 56,658 $ 47,182 Operating Partnership net income 529 425 1,405 1,305 Numerator for earnings per share - diluted $ 21,893 $ 16,007 $ 58,063 $ 48,487 Denominator for earnings per share - basic and diluted: Weighted average number of shares outstanding - basic 217,406,657 208,187,129 214,616,482 202,717,190 Effect of dilutive securities: Noncontrolling interest - Operating Partnership units 5,406,070 5,643,669 5,498,046 5,655,870 Restricted common shares 98,597 70,819 95,999 72,522 Restricted share units 1,080,725 1,228,351 1,189,122 1,109,478 Denominator for earnings per share - diluted: 223,992,049 215,129,968 221,399,649 209,555,060 Earnings per share - basic $ 0.10 $ 0.07 $ 0.26 $ 0.23 Earnings per share - diluted $ 0.10 $ 0.07 $ 0.26 $ 0.23 |
Organization and Business - Add
Organization and Business - Additional Information (Details) - $ / shares | Sep. 30, 2021 | Dec. 31, 2020 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Common stock, shares authorized (in shares) | 500,000,000 | 500,000,000 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Organization and Business - ATM
Organization and Business - ATM Program (Details) - Private Placement - ATM Program - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||
May 31, 2021 | Nov. 30, 2019 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2021 | |
Maximum | ||||||
Class of Stock [Line Items] | ||||||
Aggregate offering price of common stock | $ 500,000,000 | $ 500,000,000 | ||||
Operating Partnership | ||||||
Class of Stock [Line Items] | ||||||
Common shares sold (in shares) | 0 | 4,532,343 | 2,887,296 | 7,419,639 | ||
Weighted average price (in dollars per share) | $ 0 | $ 18.39 | $ 18.32 | $ 18.36 | ||
Proceeds from issuance of common stock | $ 0 | $ 82,519,000 | $ 52,358,000 | $ 134,877,000 | ||
Sale of stock, remaining authorized amount | $ 465,300,000 | $ 465,300,000 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies - Noncontrolling Interests (Details) - USD ($) $ in Thousands | Jan. 04, 2021 | Jan. 09, 2018 | Sep. 30, 2021 | Sep. 30, 2020 |
Business Acquisition [Line Items] | ||||
Purchase of Series A Preferred Units | $ 4,661 | $ 0 | ||
Physicians Realty Trust | ||||
Business Acquisition [Line Items] | ||||
Percentage of interest held | 97.60% | |||
Hazelwood Medical commons | Hazelwood Medical commons | ||||
Business Acquisition [Line Items] | ||||
Number of units issued for funding purchase price (in shares) | 116,110 | |||
Hazelwood Medical commons | Series A Preferred Stock | ||||
Business Acquisition [Line Items] | ||||
Purchase of Series A Preferred Units | $ 25,300 | |||
Preferred units, outstanding (in shares) | 0 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Dividends and Distributions (Details) - $ / shares | Sep. 22, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 |
Accounting Policies [Abstract] | |||||
Dividends and distributions declared per common share and OP Unit (in dollars per share) | $ 0.23 | $ 0.23 | $ 0.23 | $ 0.69 | $ 0.69 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Impairment of Intangible and Long-Lived Assets (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Accounting Policies [Abstract] | ||||
Impairment loss | $ 340,000 | $ 0 | $ 340,000 | $ 0 |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Assets Held for Sale (Details) | Sep. 30, 2021property |
Accounting Policies [Abstract] | |
Number of real estate properties held for sale | 4 |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies - Real Estate Loans Receivable, Net (Details) $ in Thousands | Sep. 30, 2021USD ($)loan | Jun. 30, 2021USD ($) | Mar. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Sep. 30, 2020USD ($) | Jun. 30, 2020USD ($) | Mar. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Property, Plant and Equipment [Line Items] | ||||||||
Cumulative effect of changes in accounting | $ (2,757,911) | $ (2,783,163) | $ (2,735,231) | $ (2,715,002) | $ (2,715,183) | $ (2,744,082) | $ (2,675,425) | $ (2,480,984) |
Financing receivable, allowance for credit loss | $ 100 | |||||||
Cumulative effect of changes in accounting standard | ||||||||
Property, Plant and Equipment [Line Items] | ||||||||
Cumulative effect of changes in accounting | 147 | |||||||
Mezzanine Loan Receivable | ||||||||
Property, Plant and Equipment [Line Items] | ||||||||
Number of mezzanine loans collateralized | loan | 22 | |||||||
Construction Loans | ||||||||
Property, Plant and Equipment [Line Items] | ||||||||
Number of mezzanine loans collateralized | loan | 1 | |||||||
Term Loan Receivable | ||||||||
Property, Plant and Equipment [Line Items] | ||||||||
Number of mezzanine loans collateralized | loan | 3 | |||||||
Retained Earnings | ||||||||
Property, Plant and Equipment [Line Items] | ||||||||
Cumulative effect of changes in accounting | $ 751,150 | $ 722,587 | $ 689,769 | $ 658,171 | $ 627,884 | $ 595,117 | $ 563,742 | 529,194 |
Retained Earnings | Cumulative effect of changes in accounting standard | Accounting Standards Update 2016-13 [Member] | ||||||||
Property, Plant and Equipment [Line Items] | ||||||||
Cumulative effect of changes in accounting | $ 100 |
Summary of Significant Accoun_8
Summary of Significant Accounting Policies - Rental and Related Revenues (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2020 | Sep. 30, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | ||||
Straight line rent receivable, net | $ 93,747 | $ 86,551 | ||
Allowance for loan and lease loss, recovery of bad debts | $ 400 | $ 500 |
Summary of Significant Accoun_9
Summary of Significant Accounting Policies - New Accounting Pronouncements (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Cumulative effect of changes in accounting | $ (2,757,911) | $ (2,783,163) | $ (2,735,231) | $ (2,715,002) | $ (2,715,183) | $ (2,744,082) | $ (2,675,425) | $ (2,480,984) |
Cumulative effect of changes in accounting standard | ||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Cumulative effect of changes in accounting | 147 | |||||||
Retained Earnings | ||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||||
Cumulative effect of changes in accounting | $ 751,150 | $ 722,587 | $ 689,769 | $ 658,171 | $ 627,884 | $ 595,117 | $ 563,742 | $ 529,194 |
Investment and Disposition Ac_3
Investment and Disposition Activity - Narrative (Details) $ in Thousands | 3 Months Ended | 9 Months Ended |
Sep. 30, 2021USD ($)mezzanine_loanproperty | Sep. 30, 2021USD ($)healthcarepropertypropertycondominium_unitmezzanine_loan | |
Asset Acquisition [Line Items] | ||
Number of operating healthcare properties | healthcareproperty | 8 | |
Asset acquisition, consideration transferred | $ 96,865 | |
Construction loan | 10,500 | $ 10,500 |
Payments for loans receivable and payments to acquire real estate | 144,700 | 144,700 |
Asset acquisition, capitalized costs | $ 1,600 | $ 1,600 |
Number of real estate properties held for sale | property | 4 | 4 |
Two Medical Condominium Units Acquired in 2021 | ||
Asset Acquisition [Line Items] | ||
Number of medical condominium units | condominium_unit | 3 | |
Asset acquisition, consideration transferred | $ 122,700 | |
Earn-Out Investments | ||
Asset Acquisition [Line Items] | ||
Asset acquisition, consideration transferred | 300 | |
Real Estate Loan | ||
Asset Acquisition [Line Items] | ||
Payments for (proceeds from) loans receivable | $ 8,900 | |
Number of mezzanine loans collateralized | mezzanine_loan | 3 | 3 |
Construction Loans | ||
Asset Acquisition [Line Items] | ||
Payments for (proceeds from) loans receivable | $ 5,500 | |
Previously Outstanding Construction Loan | ||
Asset Acquisition [Line Items] | ||
Payments for (proceeds from) loans receivable | $ 15,500 |
Investment and Disposition Ac_4
Investment and Disposition Activity - Summary of Investment Activity (Details) - USD ($) $ in Thousands | Sep. 23, 2021 | Aug. 30, 2021 | Aug. 18, 2021 | Sep. 30, 2021 |
Asset Acquisition [Line Items] | ||||
Asset acquisition, consideration transferred | $ 96,865 | |||
InterMed MOB - Davis Joint Venture | ||||
Asset Acquisition [Line Items] | ||||
Asset acquisition, consideration transferred | $ 7,291 | |||
Noncontrolling interest, ownership in joint venture | 49.00% | |||
Atkins Portfolio (5 MOBs) | ||||
Asset Acquisition [Line Items] | ||||
Asset acquisition, consideration transferred | $ 54,090 | |||
HonorHealth - Sonoran MOB | ||||
Asset Acquisition [Line Items] | ||||
Asset acquisition, consideration transferred | $ 31,750 | |||
Loan Investments | ||||
Asset Acquisition [Line Items] | ||||
Asset acquisition, consideration transferred | $ 3,734 |
Investment and Disposition Ac_5
Investment and Disposition Activity - Summary of Acquisition Date Fair Values (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 |
Asset Acquisition [Line Items] | |||
Land | $ 10,898 | ||
Building and improvements | 112,312 | ||
Right-of-use asset | 1,700 | ||
Prepaid expenses | 129 | ||
Net assets acquired | 137,816 | ||
1st Quarter | |||
Asset Acquisition [Line Items] | |||
Land | $ 189 | ||
Building and improvements | 917 | ||
Right-of-use asset | 0 | ||
Prepaid expenses | 0 | ||
Net assets acquired | 1,135 | ||
2nd Quarter | |||
Asset Acquisition [Line Items] | |||
Land | $ 2,655 | ||
Building and improvements | 44,743 | ||
Right-of-use asset | 0 | ||
Prepaid expenses | 129 | ||
Net assets acquired | 51,969 | ||
3rd Quarter | |||
Asset Acquisition [Line Items] | |||
Land | 8,054 | ||
Building and improvements | 66,652 | ||
Right-of-use asset | 1,700 | ||
Prepaid expenses | 0 | ||
Net assets acquired | 84,712 | ||
In-place lease intangibles | |||
Asset Acquisition [Line Items] | |||
In-place lease intangibles | 12,687 | ||
In-place lease intangibles | 1st Quarter | |||
Asset Acquisition [Line Items] | |||
In-place lease intangibles | 29 | ||
In-place lease intangibles | 2nd Quarter | |||
Asset Acquisition [Line Items] | |||
In-place lease intangibles | 4,442 | ||
In-place lease intangibles | 3rd Quarter | |||
Asset Acquisition [Line Items] | |||
In-place lease intangibles | 8,216 | ||
Above-market leases | |||
Asset Acquisition [Line Items] | |||
Above market in-place lease intangibles | 241 | ||
Above-market leases | 1st Quarter | |||
Asset Acquisition [Line Items] | |||
Above market in-place lease intangibles | 0 | ||
Above-market leases | 2nd Quarter | |||
Asset Acquisition [Line Items] | |||
Above market in-place lease intangibles | 0 | ||
Above-market leases | 3rd Quarter | |||
Asset Acquisition [Line Items] | |||
Above market in-place lease intangibles | 241 | ||
Below-market leases | |||
Asset Acquisition [Line Items] | |||
Below market in-place lease intangibles | (151) | ||
Below-market leases | 1st Quarter | |||
Asset Acquisition [Line Items] | |||
Below market in-place lease intangibles | $ 0 | ||
Below-market leases | 2nd Quarter | |||
Asset Acquisition [Line Items] | |||
Below market in-place lease intangibles | $ 0 | ||
Below-market leases | 3rd Quarter | |||
Asset Acquisition [Line Items] | |||
Below market in-place lease intangibles | $ (151) |
Investment and Disposition Ac_6
Investment and Disposition Activity - Assets Held for Sale (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Business Combination and Asset Acquisition [Abstract] | ||
Disposal Group, Including Discontinued Operations, Land and Improvements | $ 7,660 | |
Disposal Group, Including Discontinued Operations, Building and Improvements | 49,930 | |
Disposal Group, Including Discontinued Operations, Tenant Improvements | 455 | |
Disposal Group, Including Discontinued Operations, Acquired Lease Intangibles | 3,141 | |
Real Estate Held For Sale, Gross | 61,186 | |
Accumulated depreciation | (16,480) | |
Real estate held for sale | $ 44,706 | $ 0 |
Intangibles - Summary of Carryi
Intangibles - Summary of Carrying Amount of Intangible Assets and Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Liabilities | ||
Below-market leases, net | $ 5,829 | $ 6,641 |
In-place leases | ||
Assets: | ||
Cost | 364,750 | 362,837 |
Accumulated Amortization | (193,231) | (173,862) |
Net | 171,519 | 188,975 |
Above-market leases | ||
Assets: | ||
Cost | 43,586 | 43,386 |
Accumulated Amortization | (23,373) | (20,670) |
Net | 20,213 | 22,716 |
Leasehold interest | ||
Assets: | ||
Cost | 712 | 712 |
Accumulated Amortization | (406) | (361) |
Net | 306 | 351 |
Below-market leases | ||
Liabilities | ||
Below-market leases, cost | 15,980 | 15,882 |
Below-market leases, accumulated amortization | (10,151) | (9,241) |
Below-market leases, net | $ 5,829 | $ 6,641 |
Intangibles - Summary of Acquir
Intangibles - Summary of Acquired Amortization (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Amortization expense related to in-place leases | ||||
Intangibles | ||||
Amortization expense related to in-place leases | $ 8,103 | $ 9,088 | $ 24,590 | $ 26,190 |
Decrease in rental income related to above-market leases | ||||
Intangibles | ||||
Decrease of rental income | 897 | 954 | 2,744 | 2,918 |
Decrease in rental income related to leasehold interest | ||||
Intangibles | ||||
Decrease of rental income | 15 | 15 | 45 | 45 |
Increase in rental income related to below-market leases | ||||
Intangibles | ||||
Increase in rental income related to below-market leases | $ 324 | $ 397 | $ 963 | $ 1,102 |
Intangibles - Additional Inform
Intangibles - Additional Information (Details) | 9 Months Ended |
Sep. 30, 2021property | |
Intangibles | |
Number of real estate properties held for sale | 4 |
In-place lease intangibles | |
Intangibles | |
Weighted average amortization period for lease intangibles | 8 years |
Above-market leases | |
Intangibles | |
Weighted average amortization period for lease intangibles | 8 years |
Leasehold interest | |
Intangibles | |
Weighted average amortization period for lease intangibles | 8 years |
Increase in rental income related to below-market leases | |
Intangibles | |
Weighted average amortization period for lease intangibles | 7 years |
Intangibles - Future Aggregate
Intangibles - Future Aggregate Net Amortization of Acquired Lease Intangibles (Details) $ in Thousands | Sep. 30, 2021USD ($) |
Net Decrease in Revenue | |
2021 | $ 547 |
2022 | 1,963 |
2023 | 1,656 |
2024 | 1,589 |
2025 | 1,590 |
Thereafter | 7,345 |
Total | 14,690 |
Net Increase in Expenses | |
2021 | 7,954 |
2022 | 29,276 |
2023 | 26,546 |
2024 | 23,350 |
2025 | 19,817 |
Thereafter | 64,576 |
Total | $ 171,519 |
Other Assets - Schedule of Othe
Other Assets - Schedule of Other Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Other Assets, Unclassified [Abstract] | ||
Straight line rent receivable, net | $ 93,747 | $ 86,551 |
Leasing commissions, net | 11,441 | 9,282 |
Prepaid expenses | 8,943 | 9,401 |
Lease inducements, net | 8,518 | 9,396 |
Escrows | 1,546 | 1,507 |
Notes receivable, net | 1,045 | 23,760 |
Other | 5,249 | 4,103 |
Total | $ 130,489 | $ 144,000 |
Debt - Summary of Debt (Details
Debt - Summary of Debt (Details) | Jul. 07, 2016 | Sep. 30, 2021USD ($)healthcareproperty | Dec. 31, 2020USD ($)healthcareproperty | Sep. 24, 2021USD ($) |
Debt | ||||
Long-term debt, gross | $ 1,434,168,000 | $ 1,449,001,000 | ||
Unamortized deferred financing costs | (8,925,000) | (5,369,000) | ||
Unamortized discounts | (4,366,000) | (4,855,000) | ||
Unamortized fair value adjustments | 26,000 | 73,000 | ||
Total debt | $ 1,420,903,000 | 1,438,850,000 | ||
2021 Third Amended and Restated Credit Agreement | ||||
Debt | ||||
Current borrowing capacity | $ 1,300,000,000 | |||
2018 Credit Agreement Amendment | London Interbank Offered Rate (LIBOR) | ||||
Debt | ||||
Reference rate (as a percent) | 0.85% | |||
Mortgages | ||||
Debt | ||||
Long-term debt, gross | $ 50,168,000 | 58,001,000 | ||
Mortgages | Fixed interest rate mortgage notes | ||||
Debt | ||||
Long-term debt, gross | $ 44,420,000 | $ 51,896,000 | ||
Weighted average interest rate | 4.78% | |||
Pledged assets separately reported real estate pledged as collateral number | healthcareproperty | 3 | 4 | ||
Pledged assets, not separately reported, real estate | $ 97,000,000 | $ 110,300,000 | ||
Mortgages | Fixed interest rate mortgage notes | Minimum | ||||
Debt | ||||
Interest rate (as a percent) | 4.63% | |||
Mortgages | Fixed interest rate mortgage notes | Maximum | ||||
Debt | ||||
Interest rate (as a percent) | 5.50% | |||
Mortgages | Variable interest mortgage note | ||||
Debt | ||||
Long-term debt, gross | $ 5,748,000 | $ 6,105,000 | ||
Weighted average interest rate | 2.83% | 2.90% | ||
Pledged assets separately reported real estate pledged as collateral number | healthcareproperty | 1 | |||
Pledged assets, not separately reported, real estate | $ 8,100,000 | $ 8,300,000 | ||
Mortgages | Variable interest mortgage note | London Interbank Offered Rate (LIBOR) | ||||
Debt | ||||
Reference rate (as a percent) | 2.75% | |||
Mortgages | Mortgage notes bearing fixed interest rate due in 2022 and 2024 | ||||
Debt | ||||
Weighted average interest rate | 4.79% | |||
Mortgages | Mortgage notes bearing fixed interest rate due in 2022 and 2024 | Minimum | ||||
Debt | ||||
Interest rate (as a percent) | 4.63% | |||
Mortgages | Mortgage notes bearing fixed interest rate due in 2022 and 2024 | Maximum | ||||
Debt | ||||
Interest rate (as a percent) | 5.50% | |||
Revolving credit facility | ||||
Debt | ||||
Current borrowing capacity | $ 841,000,000 | |||
Revolving credit facility | Unsecured Revolving Credit Facility Bearing Variable Interest | ||||
Debt | ||||
Long-term debt, gross | $ 159,000,000 | $ 166,000,000 | ||
Revolving credit facility | 2021 Third Amended and Restated Credit Agreement | ||||
Debt | ||||
Reference rate (as a percent) | 0.85% | |||
Current borrowing capacity | $ 1,000,000,000 | |||
Revolving credit facility | $850.0 million revolving credit facility due September 2022 | ||||
Debt | ||||
Reference rate (as a percent) | 0.90% | |||
Current borrowing capacity | $ 850,000,000 | |||
Senior notes | ||||
Debt | ||||
Total debt | $ 975,000,000 | |||
Senior notes | $400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027 | ||||
Debt | ||||
Long-term debt, gross | 400,000,000 | 400,000,000 | ||
Debt instrument, face amount | $ 400,000,000 | |||
Interest rate (as a percent) | 4.30% | |||
Senior notes | $350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028 | ||||
Debt | ||||
Long-term debt, gross | $ 350,000,000 | 350,000,000 | ||
Debt instrument, face amount | $ 350,000,000 | |||
Interest rate (as a percent) | 3.95% | |||
Senior notes | $150 million senior unsecured notes bearing fixed interest of 4.03% to 4.74%, due January 2023 to 2031 | ||||
Debt | ||||
Long-term debt, gross | $ 150,000,000 | 150,000,000 | ||
Debt instrument, face amount | $ 150,000,000 | |||
Senior notes | $150 million senior unsecured notes bearing fixed interest of 4.03% to 4.74%, due January 2023 to 2031 | Minimum | ||||
Debt | ||||
Interest rate (as a percent) | 4.03% | |||
Senior notes | $150 million senior unsecured notes bearing fixed interest of 4.03% to 4.74%, due January 2023 to 2031 | Maximum | ||||
Debt | ||||
Interest rate (as a percent) | 4.74% | |||
Senior notes | $75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027 | ||||
Debt | ||||
Long-term debt, gross | $ 75,000,000 | 75,000,000 | ||
Debt instrument, face amount | $ 75,000,000 | |||
Senior notes | $75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027 | Minimum | ||||
Debt | ||||
Interest rate (as a percent) | 4.09% | |||
Senior notes | $75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027 | Maximum | ||||
Debt | ||||
Interest rate (as a percent) | 4.24% | |||
Unsecured Debt | $250 million unsecured term borrowing bearing fixed interest, due June 2023 | ||||
Debt | ||||
Long-term debt, gross | $ 250,000,000 | $ 250,000,000 | ||
Debt instrument, face amount | $ 250,000,000 | |||
Interest rate (as a percent) | 2.07% | |||
Unsecured Debt | 2018 Credit Agreement Amendment | London Interbank Offered Rate (LIBOR) | ||||
Debt | ||||
Reference rate (as a percent) | 1.00% | 1.00% |
Debt - Additional Information (
Debt - Additional Information (Details) | Jul. 07, 2016USD ($) | Sep. 30, 2021USD ($)extensionOptionRate | Sep. 30, 2020USD ($) | Sep. 30, 2021USD ($)extensionOptionRate | Sep. 30, 2020USD ($) | Sep. 24, 2021USD ($) | Dec. 31, 2020USD ($) | Aug. 07, 2018 |
Debt | ||||||||
Long-term debt | $ 1,420,903,000 | $ 1,420,903,000 | $ 1,438,850,000 | |||||
Long-term debt, gross | 1,434,168,000 | 1,434,168,000 | 1,449,001,000 | |||||
Interest expense, debt | 12,900,000 | $ 13,100,000 | $ 39,000,000 | $ 41,700,000 | ||||
2021 Third Amended and Restated Credit Agreement | ||||||||
Debt | ||||||||
Current borrowing capacity | $ 1,300,000,000 | |||||||
Maximum borrowing capacity as a percentage of maximum principal amount | 10.00% | |||||||
Accordion feature, increase limit | 500,000,000 | |||||||
Maximum borrowing capacity under accordion feature | 1,750,000,000 | |||||||
2018 Credit Agreement Amendment | ||||||||
Debt | ||||||||
Unused fee (as a percent) | 0.20% | |||||||
2018 Credit Agreement Amendment | London Interbank Offered Rate (LIBOR) | ||||||||
Debt | ||||||||
Reference rate (as a percent) | 0.85% | |||||||
Revolving credit facility | ||||||||
Debt | ||||||||
Current borrowing capacity | $ 841,000,000 | $ 841,000,000 | ||||||
Number of extension options | extensionOption | 2 | 2 | ||||||
Term of extension option | 6 months | |||||||
Amount outstanding | $ 159,000,000 | $ 159,000,000 | ||||||
Revolving credit facility | 2021 Third Amended and Restated Credit Agreement | ||||||||
Debt | ||||||||
Current borrowing capacity | 1,000,000,000 | |||||||
Reference rate (as a percent) | 0.85% | |||||||
Term Loan | ||||||||
Debt | ||||||||
Amount outstanding | $ 250,000,000 | $ 250,000,000 | $ 250,000,000 | |||||
Term Loan | 2021 Third Amended and Restated Credit Agreement | ||||||||
Debt | ||||||||
Current borrowing capacity | $ 250,000,000 | |||||||
Term Loan | 2018 Credit Agreement Amendment | ||||||||
Debt | ||||||||
Debt instrument, term | 7 years | |||||||
Unsecured Debt | 2018 Credit Agreement Amendment | London Interbank Offered Rate (LIBOR) | ||||||||
Debt | ||||||||
Reference rate (as a percent) | 1.00% | 1.00% | ||||||
Unsecured Debt | $250 million unsecured term borrowing bearing fixed interest, due June 2023 | ||||||||
Debt | ||||||||
Interest rate (as a percent) | 2.07% | 2.07% | ||||||
Long-term debt, gross | $ 250,000,000 | $ 250,000,000 | $ 250,000,000 | |||||
Senior notes | ||||||||
Debt | ||||||||
Long-term debt | 975,000,000 | 975,000,000 | ||||||
Senior notes | Senior Notes Due 2023 | ||||||||
Debt | ||||||||
Long-term debt | 15,000,000 | 15,000,000 | ||||||
Senior notes | Senior Notes Due 2025 | ||||||||
Debt | ||||||||
Long-term debt | 25,000,000 | 25,000,000 | ||||||
Senior notes | Senior Notes Due 2026 | ||||||||
Debt | ||||||||
Long-term debt | 70,000,000 | 70,000,000 | ||||||
Senior notes | Senior Notes Due 2027 | ||||||||
Debt | ||||||||
Long-term debt | 425,000,000 | 425,000,000 | ||||||
Senior notes | Senior Notes Due 2028 | ||||||||
Debt | ||||||||
Long-term debt | 395,000,000 | 395,000,000 | ||||||
Senior notes | Senior Notes Due 2031 | ||||||||
Debt | ||||||||
Long-term debt | $ 45,000,000 | $ 45,000,000 | ||||||
Interest Rate Swap | Unsecured Debt | ||||||||
Debt | ||||||||
Effective fixed interest rate (as a percent) | Rate | 2.07% | 2.07% | ||||||
Interest Rate Swap | Unsecured Debt | London Interbank Offered Rate (LIBOR) | ||||||||
Debt | ||||||||
Effective fixed interest rate (as a percent) | 1.07% | 1.07% | 1.07% | |||||
Operating Partnership | Revolving credit facility | ||||||||
Debt | ||||||||
Interest rate at end of period (as a percent) | 3.48% | 3.48% | ||||||
Operating Partnership | Revolving credit facility | London Interbank Offered Rate (LIBOR) | ||||||||
Debt | ||||||||
Reference rate (as a percent) | 0.08% |
Debt - Trust Investment Grade R
Debt - Trust Investment Grade Rating (Details) | 9 Months Ended |
Sep. 30, 2021 | |
At Least A- or A3 | Adjusted LIBOR rate loans and letter of credit | London Interbank Offered Rate (LIBOR) | |
Debt | |
Reference rate (as a percent) | 0.725% |
At Least A- or A3 | Adjusted LIBOR rate term loans and letter of credit | London Interbank Offered Rate (LIBOR) | |
Debt | |
Reference rate (as a percent) | 0.85% |
At Least BBB+ or Baa1 | Adjusted LIBOR rate loans and letter of credit | London Interbank Offered Rate (LIBOR) | |
Debt | |
Reference rate (as a percent) | 0.775% |
At Least BBB+ or Baa1 | Adjusted LIBOR rate term loans and letter of credit | London Interbank Offered Rate (LIBOR) | |
Debt | |
Reference rate (as a percent) | 0.90% |
At Least BBB or Baa2 | Adjusted LIBOR rate loans and letter of credit | London Interbank Offered Rate (LIBOR) | |
Debt | |
Reference rate (as a percent) | 0.85% |
At Least BBB or Baa2 | Adjusted LIBOR rate term loans and letter of credit | London Interbank Offered Rate (LIBOR) | |
Debt | |
Reference rate (as a percent) | 1.00% |
At Least BBB- or Baa3 | Adjusted LIBOR rate loans and letter of credit | London Interbank Offered Rate (LIBOR) | |
Debt | |
Reference rate (as a percent) | 1.05% |
At Least BBB- or Baa3 | Adjusted LIBOR rate term loans and letter of credit | London Interbank Offered Rate (LIBOR) | |
Debt | |
Reference rate (as a percent) | 1.25% |
Below BBB- or Baa3 | Adjusted LIBOR rate loans and letter of credit | London Interbank Offered Rate (LIBOR) | |
Debt | |
Reference rate (as a percent) | 1.40% |
Below BBB- or Baa3 | Adjusted LIBOR rate term loans and letter of credit | London Interbank Offered Rate (LIBOR) | |
Debt | |
Reference rate (as a percent) | 1.65% |
Applicable Margin for Revolving Loans: Base Rate Loans | At Least A- or A3 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.00% |
Applicable Margin for Revolving Loans: Base Rate Loans | At Least BBB+ or Baa1 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.00% |
Applicable Margin for Revolving Loans: Base Rate Loans | At Least BBB or Baa2 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.00% |
Applicable Margin for Revolving Loans: Base Rate Loans | At Least BBB- or Baa3 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.05% |
Applicable Margin for Revolving Loans: Base Rate Loans | Below BBB- or Baa3 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.40% |
Applicable Margin for Term Loans: Base Rate Loans | At Least A- or A3 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.00% |
Applicable Margin for Term Loans: Base Rate Loans | At Least BBB+ or Baa1 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.00% |
Applicable Margin for Term Loans: Base Rate Loans | At Least BBB or Baa2 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.00% |
Applicable Margin for Term Loans: Base Rate Loans | At Least BBB- or Baa3 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.25% |
Applicable Margin for Term Loans: Base Rate Loans | Below BBB- or Baa3 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.65% |
Debt - Scheduled Principal Paym
Debt - Scheduled Principal Payments (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Debt Disclosure [Abstract] | ||
2021 | $ 463 | |
2022 | 20,825 | |
2023 | 266,008 | |
2024 | 23,669 | |
2025 | 184,476 | |
Thereafter | 938,727 | |
Total Payments | $ 1,434,168 | $ 1,449,001 |
Derivatives - Additional Inform
Derivatives - Additional Information (Details) | Sep. 30, 2021instrument |
Interest Rate Swap | |
Derivative [Line Items] | |
Outstanding interest rate swap contracts designated as cash flow hedges | 5 |
Derivatives - Location and Aggr
Derivatives - Location and Aggregate Fair Value of Interest Rate Swaps (Details) - USD ($) | Jul. 07, 2016 | Sep. 30, 2021 | Dec. 31, 2020 |
Derivative [Line Items] | |||
Total notional amount | $ 250,000,000 | ||
Effective date | Jul. 7, 2016 | ||
Maturity date | Jun. 10, 2023 | ||
Interest Rate Swap | Carrying Amount | |||
Derivative [Line Items] | |||
Liability balance at September 30, 2021 (included in Accrued expenses and other liabilities) | $ 3,567,000 | $ 5,317,000 | |
Liability balance at December 31, 2020 (included in Accrued expenses and other liabilities) | $ 3,567,000 | $ 5,317,000 | |
London Interbank Offered Rate (LIBOR) | 2018 Credit Agreement Amendment | |||
Derivative [Line Items] | |||
Reference rate (as a percent) | 0.85% | ||
Unsecured Debt | Interest Rate Swap | |||
Derivative [Line Items] | |||
Effective fixed interest rate (as a percent) | 2.07% | ||
Unsecured Debt | London Interbank Offered Rate (LIBOR) | 2018 Credit Agreement Amendment | |||
Derivative [Line Items] | |||
Reference rate (as a percent) | 1.00% | 1.00% | |
Unsecured Debt | London Interbank Offered Rate (LIBOR) | Interest Rate Swap | |||
Derivative [Line Items] | |||
Effective fixed interest rate (as a percent) | 1.07% | 1.07% |
Accrued Expenses and Other Li_3
Accrued Expenses and Other Liabilities - Schedule of Accrued Expense and Other Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Other Liabilities Disclosure [Abstract] | ||
Real estate taxes payable | $ 27,033 | $ 23,436 |
Prepaid rent | 18,606 | 22,248 |
Accrued interest | 5,746 | 16,009 |
Accrued expenses | 5,619 | 5,721 |
Accrued incentive compensation | 4,950 | 1,945 |
Security deposits | 3,885 | 3,714 |
Interest rate swap | 3,567 | 5,317 |
Tenant improvement allowances | 1,857 | 1,917 |
Embedded derivative | 0 | 4,944 |
Other | 8,358 | 6,678 |
Total | $ 79,621 | $ 91,929 |
Stock-based Compensation - Addi
Stock-based Compensation - Additional Information (Details) | Apr. 30, 2019shares |
Restricted common shares | 2013 Plan | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Maximum number of shares authorized (in shares) | 7,000,000 |
Stock-based Compensation - Rest
Stock-based Compensation - Restricted Common Shares (Narrative) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Non-cash share compensation | $ 10,840 | $ 9,161 | ||
2013 Plan | Restricted common shares | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Granted (in shares) | 224,163 | |||
Non-cash share compensation | $ 1,000 | $ 900 | $ 2,800 | $ 2,600 |
Unrecognized compensation expense | $ 2,400 | $ 2,400 | ||
2013 Plan | Restricted common shares | Minimum | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting period | 1 year | |||
2013 Plan | Restricted common shares | Maximum | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting period | 3 years | |||
Officers and Certain Employees | 2013 Plan | Restricted common shares | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Granted (in shares) | 224,163 | |||
Grant date value | $ 3,900 |
Stock-based Compensation - Summ
Stock-based Compensation - Summary of the Status of the Trust's Non-Vested Restricted Common Shares (Details) - 2013 Plan - Restricted common shares | 9 Months Ended |
Sep. 30, 2021$ / sharesshares | |
Common Shares | |
Non-vested at the beginning of the period (in shares) | shares | 215,822 |
Granted (in shares) | shares | 224,163 |
Vested (in shares) | shares | (185,968) |
Non-vested at the end of the period (in shares) | shares | 254,017 |
Weighted Average Grant Date Fair Value | |
Non-vested at beginning of period (in dollars per share) | $ / shares | $ 18.73 |
Granted (in dollars per share) | $ / shares | 17.42 |
Vested (in dollars per share) | $ / shares | 18.94 |
Non-vested at end of period (in dollars per share) | $ / shares | $ 17.42 |
Stock-based Compensation - Re_2
Stock-based Compensation - Restricted Share Units (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||
Mar. 31, 2021 | Jan. 31, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Non-cash share compensation | $ 10,840 | $ 9,161 | ||||
2013 Plan | Restricted share units (RSUs) | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Non-cash share compensation | $ 2,700 | $ 2,200 | 8,000 | $ 6,500 | ||
Unrecognized compensation expense | $ 12,700 | $ 12,700 | ||||
2013 Plan | Market Based Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche One | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Granted (in dollars per share) | $ 27.53 | |||||
2013 Plan | Market Based Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche Two | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Granted (in dollars per share) | $ 30.82 | |||||
Officers and Certain Employees | 2013 Plan | Restricted share units (RSUs) | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Granted (in shares) | 265,275 | |||||
Vesting period | 3 years | 1 year | ||||
Officers and Certain Employees | 2013 Plan | Performance based restricted stock units (RSUs) | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Performance conditions grant date fair value (in dollars per share) | $ 17.21 | |||||
Vesting percentage | 60.00% | |||||
Granted (in dollars per share) | $ 22 | |||||
Percentage of restricted share units issued to trustees | 100.00% | |||||
Officers and Certain Employees | 2013 Plan | Market Based Restricted Stock Units (RSUs) | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Vesting percentage | 40.00% | |||||
Trustees | 2013 Plan | Restricted share units (RSUs) | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Granted (in shares) | 43,582 | 13,343 | ||||
Number of dividend equivalent included in each award (in shares) | 1 | 1 | ||||
Vesting period | 2 years | |||||
Trustees | 2013 Plan | Performance based restricted stock units (RSUs) | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Performance conditions grant date fair value (in dollars per share) | $ 17.80 |
Stock-based Compensation - Re_3
Stock-based Compensation - Restricted Share Assumptions (Details) - 2013 Plan - Restricted share units (RSUs) | 1 Months Ended |
Mar. 31, 2021$ / shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Volatility | 33.30% |
Expected term in years | 2 years 10 months 2 days |
Risk-free rate | 0.25% |
Share price (per share) | $ 17.21 |
Stock-based Compensation - Su_2
Stock-based Compensation - Summary of Activity in the Trust's Restricted Share Units (Details) - $ / shares | 9 Months Ended | |
Sep. 30, 2021 | Dec. 31, 2020 | |
Weighted Average Grant Date Fair Value | ||
Common stock, shares issued (in shares) | 217,409,035 | 209,550,592 |
2013 Plan | Executive Awards | ||
Restricted Share Units | ||
Non-vested at the beginning of the period (in shares) | 964,139 | |
Granted (in shares) | 265,275 | |
Vested (in shares) | (252,844) | |
Non-vested at the end of the period (in shares) | 976,570 | |
Weighted Average Grant Date Fair Value | ||
Non-vested at beginning of period (in dollars per share) | $ 21.17 | |
Granted (in dollars per share) | 22 | |
Vested (in dollars per share) | 16.58 | |
Non-vested at end of period (in dollars per share) | $ 22.59 | |
Common stock, shares issued (in shares) | 399,165 | |
Restricted stock, shares issued net of shares for tax withholdings (in shares) | 162,173 | |
2013 Plan | Trustee Awards | ||
Restricted Share Units | ||
Non-vested at the beginning of the period (in shares) | 59,820 | |
Granted (in shares) | 56,925 | |
Vested (in shares) | (40,394) | |
Non-vested at the end of the period (in shares) | 76,351 | |
Weighted Average Grant Date Fair Value | ||
Non-vested at beginning of period (in dollars per share) | $ 18.81 | |
Granted (in dollars per share) | 17.35 | |
Vested (in dollars per share) | 18.57 | |
Non-vested at end of period (in dollars per share) | $ 17.84 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021USD ($)instrumentpropertyasset | Sep. 30, 2020USD ($) | Sep. 30, 2021USD ($)instrumentpropertyasset | Sep. 30, 2020USD ($) | |
Fair value of other financial instruments | ||||
Impairment loss | $ 340,000 | $ 0 | $ 340,000 | $ 0 |
Number of real estate properties held for sale | property | 4 | 4 | ||
Fair value, measurements, nonrecurring | ||||
Fair value of other financial instruments | ||||
Number of assets measured at fair value | asset | 1 | 1 | ||
Assets subject to impairment, carrying value | $ 2,300,000 | $ 2,300,000 | ||
Interest Rate Swap | ||||
Fair value of other financial instruments | ||||
Outstanding interest rate swap contracts designated as cash flow hedges | instrument | 5 | 5 |
Fair Value Measurements - Fair
Fair Value Measurements - Fair Value of Company's Financial Instruments (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Assets: | ||
Notes receivable, net | $ 1,045 | $ 23,760 |
Liabilities: | ||
Credit facility | (401,548) | (412,322) |
Notes payable | (969,313) | (968,653) |
Mortgage debt | (50,042) | (57,875) |
Carrying Amount | ||
Assets: | ||
Real estate loans receivable, net | 181,125 | 198,800 |
Notes receivable, net | 1,045 | 23,760 |
Liabilities: | ||
Credit facility | (409,000) | (416,000) |
Notes payable | (975,000) | (975,000) |
Mortgage debt | (50,194) | (58,074) |
Carrying Amount | Derivative liabilities | ||
Liabilities: | ||
Derivative liabilities | (3,567) | (10,261) |
Fair Value | ||
Assets: | ||
Real estate loans receivable, net | 177,859 | 198,814 |
Notes receivable, net | 1,045 | 23,760 |
Liabilities: | ||
Credit facility | (409,000) | (416,000) |
Notes payable | (1,066,869) | (1,063,367) |
Mortgage debt | (51,458) | (59,651) |
Fair Value | Derivative liabilities | ||
Liabilities: | ||
Derivative liabilities | $ (3,567) | $ (10,261) |
Tenant Operating Leases - Sched
Tenant Operating Leases - Schedule of Future Minimum Rental Payments (Details) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021USD ($)property | Sep. 30, 2020USD ($) | Sep. 30, 2021USD ($)property | Sep. 30, 2020USD ($) | |
Leases [Abstract] | ||||
Number of real estate properties held for sale | property | 4 | 4 | ||
2021 | $ 77,498 | $ 77,498 | ||
2022 | 305,188 | 305,188 | ||
2023 | 297,695 | 297,695 | ||
2024 | 285,362 | 285,362 | ||
2025 | 269,862 | 269,862 | ||
Thereafter | 961,607 | 961,607 | ||
Total | 2,197,212 | 2,197,212 | ||
Operating lease, lease income | 110,300 | $ 104,400 | 326,000 | $ 311,900 |
Operating lease, variable lease income | $ 29,200 | $ 26,300 | $ 84,000 | $ 76,100 |
Rent Expense - Additional Infor
Rent Expense - Additional Information (Details) | 9 Months Ended |
Sep. 30, 2021leaseproperty | |
Leases [Abstract] | |
Number of properties subject to parking lease | 2 |
Number of properties subject to air space lease | 1 |
Number of properties subject to ground leases | 82 |
Number of office space leases | lease | 9 |
Maximum lease terms | 86 years |
Operating lease, weighted average remaining lease term | 43 years |
Operating lease, weighted average discount rate, percent | 4.40% |
Number of real estate properties held for sale | 4 |
Rent Expense - Schedule of Futu
Rent Expense - Schedule of Future Minimum Lease Obligations (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Leases [Abstract] | ||
2021 | $ 849 | |
2022 | 3,719 | |
2023 | 3,693 | |
2024 | 3,676 | |
2025 | 3,657 | |
Thereafter | 180,378 | |
Total undiscounted lease payments | 195,972 | |
Less: Interest | (117,290) | |
Present value of lease liabilities | $ 78,682 | $ 74,116 |
Rent Expense - Lease Cost (Deta
Rent Expense - Lease Cost (Details) $ in Thousands | 9 Months Ended |
Sep. 30, 2021USD ($) | |
Leases [Abstract] | |
Fixed lease cost | $ 1,823 |
Variable lease cost | 751 |
Total lease cost | $ 2,574 |
Credit Concentration - Schedule
Credit Concentration - Schedule of ABR (Annualized Base Rent) (Details) - Sales Revenue, Services, Net $ in Thousands | 9 Months Ended |
Sep. 30, 2021USD ($)Rate | |
Customer Concentration Risk | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 309,175 |
Percent of ABR (annualized base rent) | Rate | 100.00% |
Customer Concentration Risk | CommonSpirit - CHI - Nebraska | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 17,656 |
Percent of ABR (annualized base rent) | 5.70% |
Customer Concentration Risk | Northside Hospital | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 15,245 |
Percent of ABR (annualized base rent) | 4.90% |
Customer Concentration Risk | UofL Health - Louisville, Inc. | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 12,526 |
Percent of ABR (annualized base rent) | 4.10% |
Customer Concentration Risk | US Oncology | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 11,080 |
Percent of ABR (annualized base rent) | 3.60% |
Customer Concentration Risk | Baylor Scott and White Health | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 8,156 |
Percent of ABR (annualized base rent) | 2.60% |
Customer Concentration Risk | Remaining portfolio | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 244,512 |
Percent of ABR (annualized base rent) | Rate | 79.10% |
Geographic Concentration Risk | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 309,175 |
Percent of ABR (annualized base rent) | Rate | 100.00% |
Geographic Concentration Risk | Texas | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 47,331 |
Percent of ABR (annualized base rent) | 15.30% |
Geographic Concentration Risk | Georgia | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 25,618 |
Percent of ABR (annualized base rent) | 8.30% |
Geographic Concentration Risk | Indiana | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 22,784 |
Percent of ABR (annualized base rent) | 7.40% |
Geographic Concentration Risk | Nebraska | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 18,993 |
Percent of ABR (annualized base rent) | 6.10% |
Geographic Concentration Risk | Minnesota | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 17,827 |
Percent of ABR (annualized base rent) | 5.80% |
Geographic Concentration Risk | Other | |
Concentration Risk [Line Items] | |
Total ABR (annualized base rent) | $ 176,622 |
Percent of ABR (annualized base rent) | 57.10% |
Credit Concentration - Addition
Credit Concentration - Additional Information (Details) | 9 Months Ended |
Sep. 30, 2021propertyRate | |
Concentration Risk [Line Items] | |
Number of real estate properties held for sale | property | 4 |
Sales Revenue, Services, Net | Customer Concentration Risk | |
Concentration Risk [Line Items] | |
Percent of ABR (annualized base rent) | Rate | 100.00% |
Top five tenant relationships | Sales Revenue, Services, Net | Customer Concentration Risk | |
Concentration Risk [Line Items] | |
Percent of ABR (annualized base rent) | 20.90% |
CHI Portfolio | Sales Revenue, Services, Net | Customer Concentration Risk | |
Concentration Risk [Line Items] | |
Percent of ABR (annualized base rent) | 16.50% |
Earnings Per Share - Schedule o
Earnings Per Share - Schedule of Earnings Per Share and Earnings Per Unit (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | ||
Numerator for earnings per share - basic: | |||||
Net income | $ 22,045 | $ 16,475 | $ 58,531 | $ 49,879 | |
Net income attributable to noncontrolling interests: | |||||
Operating Partnership | (529) | (425) | (1,405) | (1,305) | |
Partially owned properties | [1] | (152) | (151) | (455) | (441) |
Preferred distributions | 0 | (317) | (13) | (951) | |
Net income attributable to common shareholders | 21,364 | 15,582 | 56,658 | 47,182 | |
Numerator for earnings per share - diluted: | |||||
Numerator for earnings per share - basic | 21,364 | 15,582 | 56,658 | 47,182 | |
Operating Partnership net income | 529 | 425 | 1,405 | 1,305 | |
Numerator for earnings per share - diluted | $ 21,893 | $ 16,007 | $ 58,063 | $ 48,487 | |
Denominator for earnings per share - basic and diluted: | |||||
Weighted average number of shares outstanding - basic (in shares) | 217,406,657 | 208,187,129 | 214,616,482 | 202,717,190 | |
Effect of dilutive securities: | |||||
Noncontrolling interest - Operating Partnership units (in shares) | 5,406,070 | 5,643,669 | 5,498,046 | 5,655,870 | |
Denominator for earnings per share - diluted (in shares) | 223,992,049 | 215,129,968 | 221,399,649 | 209,555,060 | |
Earnings per share - basic (in dollars per share) | $ 0.10 | $ 0.07 | $ 0.26 | $ 0.23 | |
Earnings per share - diluted (in dollars per share) | $ 0.10 | $ 0.07 | $ 0.26 | $ 0.23 | |
Restricted common shares | |||||
Effect of dilutive securities: | |||||
Restricted common shares/units (in shares) | 98,597 | 70,819 | 95,999 | 72,522 | |
Restricted share units | |||||
Effect of dilutive securities: | |||||
Restricted common shares/units (in shares) | 1,080,725 | 1,228,351 | 1,189,122 | 1,109,478 | |
[1] | Includes amounts attributable to redeemable noncontrolling interests. |
Subsequent Events - Narrative (
Subsequent Events - Narrative (Details) $ / shares in Units, $ in Thousands | Nov. 02, 2021USD ($)property | Oct. 27, 2021USD ($)ft² | Oct. 15, 2021USD ($)ft² | Oct. 13, 2021USD ($) | Oct. 01, 2021USD ($)statebuilding | Nov. 05, 2021USD ($)$ / sharesshares | Sep. 30, 2021USD ($) | Jul. 07, 2016USD ($) |
Subsequent Event [Line Items] | ||||||||
Asset acquisition, consideration transferred | $ 96,865 | |||||||
Revolving credit facility | ||||||||
Subsequent Event [Line Items] | ||||||||
Amount outstanding | 159,000 | |||||||
Term Loan | ||||||||
Subsequent Event [Line Items] | ||||||||
Amount outstanding | $ 250,000 | $ 250,000 | ||||||
Subsequent Event | ||||||||
Subsequent Event [Line Items] | ||||||||
Payments for termination of swap agreements | $ 3,300 | |||||||
Subsequent Event | Disposal Group, Held-for-sale, Not Discontinued Operations | LifeCare 2.0 Portfolio | ||||||||
Subsequent Event [Line Items] | ||||||||
Number of real estate properties | property | 3 | |||||||
Proceeds from sale of property held-for-sale | $ 62,000 | |||||||
Disposal group, not discontinued operation, gain (loss) on disposal | $ 18,700 | |||||||
Subsequent Event | Operating Partnership | 2021 ATM Program | ||||||||
Subsequent Event [Line Items] | ||||||||
Common shares sold (in shares) | shares | 2,877,988 | |||||||
Weighted average price on sale of common shares (in USD per share) | $ / shares | $ 18.61 | |||||||
Proceeds from issuance of common stock | $ 53,000 | |||||||
Subsequent Event | Senior notes | 2.625% Senior Notes, Due November 2031 | ||||||||
Subsequent Event [Line Items] | ||||||||
Debt instrument, face amount | $ 500,000 | |||||||
Interest rate (as a percent) | 2.625% | |||||||
Debt instrument, redemption price, percentage | 99.789% | |||||||
Proceeds from issuance of long-term debt | $ 495,100 | |||||||
Subsequent Event | Revolving credit facility | ||||||||
Subsequent Event [Line Items] | ||||||||
Amount outstanding | 168,000 | |||||||
Subsequent Event | Term Loan | ||||||||
Subsequent Event [Line Items] | ||||||||
Amount outstanding | $ 250,000 | |||||||
Subsequent Event | Landmark Healthcare Companies | ||||||||
Subsequent Event [Line Items] | ||||||||
Number of medical office buildings | building | 15 | |||||||
Number of states in which operating healthcare properties are located | state | 8 | |||||||
Asset acquisition, consideration transferred | $ 764,300 | |||||||
Subsequent Event | MedCore Realty Eden Hill, LLC | ||||||||
Subsequent Event [Line Items] | ||||||||
Asset acquisition, consideration transferred | $ 33,200 | |||||||
Noncontrolling interest, ownership in joint venture | 51.00% | |||||||
Area of real estate property (square feet) | ft² | 140,205 | |||||||
Subsequent Event | Medical Office Facility, Scottsdale, Arizona | ||||||||
Subsequent Event [Line Items] | ||||||||
Asset acquisition, consideration transferred | $ 67,300 | |||||||
Area of real estate property (square feet) | ft² | 109,423 |